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ABSTRACT
A sensitive, ultraviolet, spectrophotometric, high-performance 
liquid chromatographic method (using dinitrophenyl derivatives of 
drug and metabolites) for the simultaneous determination of perhexiline 
and its major metabolites in biological fluids was developed and 
validated. The procedure was employed successfully in j)harmacokinetic 
studies of perhexiline in healthy, adult volunteers.
Following oral administration of perhexiline to human volunteers, 
considerable inter-individual variation in the rates of drug absorption 
occurs. Extensive pre-systemic metabolism was observed following drug 
ingestion, with considerable individual variation in the AUC of plasma 
perhexiline. Significantly more unchanged perhexiline was available in 
the systemic circulation following the administration of (+) perhexiline 
than after either its optical antipode or the racemate; of the three 
dosage forms the (-) enantiomer was associated with the lowest plasma 
perhexiline levels.
Perhexiline is metabolized by the cytochrome P-450 dependent mixed 
function oxidase system in the liver. In humans, cis-hydroxylation is 
generally the predominant metabolic pathway for racemic perhexiline with 
trans-hydroxylation probably playing a major role in individuals with 
impaired drug oxidative capacity. Cis-hydroxylation of perhexiline 
in humans may exhibit saturable kinetics. The metabolism of perhexiline 
exhibits complex stereoselectivity. In man, cis- and trans-hydroxylation 
are the preferred routes of metabolism following ingestion of (—) and (+) 
perhexiline respectively. The (—) enantiomer is metabolized at a faster
rate than its optical antipode either in iji vivo in humans, or jin vitro 
in man and the rat.
Drug accumulation and hence drug induced-toxicity, on .prolonged Pexid 
therapy in angina patients is more likely to occur with the (+) than 
with either the (-)enantiomer or racemate and least with the (-) 
enantiomer. Defective function of the liver monooxygenase system possibly 
due to defective cytochrome P-450-substrate interaction and/or abnormal 
microenviroment of cytochrome P-450 may be the molecular mechanism of 
impaired hydroxylation of perhexiline.
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CHAPTER 1
DRUG ABSORPTION, DISPOSITION, AND PHARMACOKINETICS IN 
HUMANS AND AN OVERVIEW OF PERHEXILINE
ABSORPTION
Drugs may be given topically, enterally, by inhalation or 
parenterally. Following administration, a drug usually has to cross 
one or more biological membranes to reach its site of action. The 
membranes may be non-cellular (e,g, cell membrane), a single layer of 
cells (e,g, gastrointestinal epithelium) or several layers of cells 
(e.g, skin) (Parke, 1981), Substances may be transported through 
membranes by:
1, Simple diffusion
2, Active transport
3, Facilitated diffusion
4, Pinocytosis
5, Filtration and
6, Solvent drag (Stenlake, 1979; Parke, 1981).
SIMPLE DIFFUSION
Diffusion is a simple passive movement from a higher to a lower 
concentration caused by the thermal agitation of the particles (C^aky,
1979). The rate of diffusion may be expressed in terms of Fick*s law:
Rate of diffusion = - K. A(C^ - C^) ^
' d
A, is the area of the diffusing surface, 
d, is the thickness of the diffusing membrane,
C^, is the drug concentration outside the membrane,
Cg, is the drug concentration inside the membrane, and
K, is the diffusion constant. The minus sign denotes loss of drug 
from the outside of the membrane.
The determinants of K include the membrane characteristics, the 
molecular weight of the drug, its steric configuration, lipid 
solubility and if ionizable, the dissociation constant (Rowland, 1978; 
Stenlake, 1979).
Most drugs are weak acids or weak bases and exist in solution as
an equilibrium between the unionized and the ionized species. According
to the concept of non-ionic diffusion, only the unionized species can
pass through the lipid rich biological membrane: transfer through the
membrane depends essentially on the lipophilicity of the drug. The
ionized molecule is thought to be too polar to penetrate the lipid
membrane. In addition to the lipophilicity of the non-ionic form,
membrane transport also depends on the dissociation constant, pK , ofa
the drug and the pH of the media on either side of the membrane (pH 
partition hypothesis) (Schanker, et aJL., 1958; Hogben, ^t al.., 1959; 
Schanker, 196l). Thus,
Q
for an acid, pH = pK - log u ------- 2
a c71
Q
and for a base, pH = pK - log i ------- 3
a c
U
where C. and C are the concentrations of the ionized and unionized drug x u  ^
respectively.
When the two phases on either side of the membrane have the same pH 
(e.g. plasma and cerebrospinal fluid), the concentrations of the ionized 
and molecular forms will be the same on both sides of the membrane at 
equilibrium. When a pH differential exists across a membrane (e.g. 
gastric fluid and plasma), basic drugs will tend to accumulate in the 
more acidic fluids and acidic drugs will tend to accumulate in the basic 
fluids.
There is evidence that ionized species, e,g, quartenary ammonium 
compounds, are also transported through lipid membranes and that this 
process may account for some drug transfer (Benet, 1973). The following 
equation expresses the influence of pH on the absorption of a weak 
electrolyte:
K = K f + K. f. ------- 4app u u 1 1
where ^he apparent first order absorption rate constant at a
given pH, f and f^ are the fraction of drug present in the unionized 
and ionized form respectively, and K and are the corresponding 
absorption rate constants. If 1 then absorption of the
undissociated drug is favoured. Carbenoxolone, a highly lipophilic 
and weakly dibasic acid, is absorbed preferentially from the gastro­
intestinal tract of the rat in the ionized form (K^/lL = 0 .26)
(Bridges, et jal., 1976).
A mechanism whereby ionic species can be absorbed through lipid- 
rich membranes is by ion-pair formation. Ion-pairs are neutral species 
formed by electrostatic attraction between oppositively charged ions in 
solution and which are sufficiently lipophilic to dissolve in non- 
aqueous media (Irwin et al«, 1969). Absorption of tetracyline by ion- 
pair formation has been reported (Klink and Colaizzi, 1973). Enhanced 
absorption of quaternary ammonium compounds (Gibaldi and Grunhofer, 1973)> 
dextromethorphan (Fiese and Perrin, 1969) and tetracycline (Perrin and 
Vallner, 1970) has been reported using an appropriate counter-ion.
ACTIVE TRANSPORT
In active transport compounds are transported against a concentration 
or electrochemical gradient by processes that require expenditure of 
energy and carrier mechanisms (Stenlake, 1979). The rate of active
transport may be expressed in the form of the Michaelis-Menten equation 
thus,
dC dC rniTT - ~ TT max L'DJdt dt • L J
K + [d ]c J
dC = rate of absorption 
dt
dC~  max = the maximum rate of absorption at high drug concentration
[d ] = the drug concentration
K = the affinity constant of the drug for the carrier,c
If K }>>)> [d], then Kc + [d] can be considered equal to Kc* Since
dC max and K are constants for a given drug, the rate of absorption by 
dt C
active transport at low drug concentrations is proportional to the drug 
concentration, i.e.
I  = UD] ----- 6
where K = _dC /  
d t / K c
At very high drug concentrations,^ becomes negligible compared with [d ]
and absorption by active transport follows zero order kinetics, at
constant and maximum speed, i.e.
dC dC -—  = _ —  max ----------7
(Ritschel, 1980; Stenlake, 1979).
Active transport is more important in drug excretion than in drug 
absorption (Creasy, 1979). Drugs which resemble natural substrates may, 
however, be absorbed by active transport. For example, . 5-fluorouracil 
is transported into cells by the mechanism that transports uracil,and 
methotrexate by the pathway that transports folate derivatives. Active 
transport systems exhibit specificity, competitive inhibition and 
saturability (Rowland and Tozer, 1980),
FACILITATED DIFFUSION
In facilitated diffusion, transport of a compound is accomplished 
with the aid of a carrier. In contrast to active transport, the 
substrate in facilitated diffusion moves in the direction of the 
concentration gradient (he Fevre, 1961). Like active transport, 
facilitated diffusion exhibits specificity, competitive inhibition 
and saturability. Facilitated diffusion allowssubstances to be 
transported across cell membranes at a rate faster than simple 
diffusion (Meyersohn, 1977). It is involved in the intestinal 
absorption of vitamin is generally not a major mechanism of
drug transport.
PINOCYTOSIS
In pinocytosis invagination of the cell membrane engulfs extra­
cellular material into vacuoles. It is probably not an important mode 
of drug uptake. Reduction of the cardio-toxicity of adriamycin has been 
reported, by incorporating the drug in liposomes; the liposomes are then 
taken up into cells by pinocytosis. Myocardial cells are thought to be 
incapable of pinocytosis and are therefore protected (Creasy, 1979).
FILTRATION
Filtration utilizes the aqueous pores in the membrane as channels of 
transport. It is purely a physical process, the driving force for 
membrane transport being provided by the prevailing pressure gradient 
(Levine, 1978). Filtration is also dependent on the size of the 
molecule to be filtered: it is involved in the transport of small
hydrophilic molecules of less than 4A in radius, e.g. urea.
SOLVENT DRAG
In the phenomenon of solvent drag, solutes (e.g. drug molecules) 
are carried along with the trans-membrane movement of water.
BUCCAL AND SUBLINGUAL ABSORPTION
Drugs may be absorbed through the mucous membrane of the mouth 
by simple diffusion into the systemic circulation. This route of drug 
administration obviates the problem of gastrointestinal and hepatic pre- 
systemic drug metabolism, resulting in greater systemic drug availability 
and hence more potent and rapid drug effect (Bogaert and Rosseel, 1972). 
Neutral, acidic and basic drugs are absorbed in accordance with the 
principles of diffusion outlined previously. There is evidence to 
suggest that ion-paired drugs may be absorbed through the buccal 
mucous membrane (Becket et al., 1967; 1968a; 1968b; Tomlinson and Davies,
1976).
GASTROINTESTINAL ABSORPTION
Most drugs are administered orally for the convenience of the 
patient. Simple diffusion is the main transport mechanism responsible 
for gastrointestinal drug absorption. Neutral drugs (e.g. ,clofibrate), 
weak acids (e.g. aspirin), weak bases (e.g. codeine phosphate) and 
highly ionized drugs are all absorbed in accordance with the concepts 
outlined under diffusion. Active transport is involved in the absorption 
of drugs which resemble natural dietary components (e.g. 5-fluorouracil). 
Vitamin B ^  is absorbed by facilitated diffusion. The role of pinocytosis 
and filtration in gastrointestinal drug absorption is not known.
Following oral administration of a drug, there is usually a delay 
before any drug appears in the systemic circulation. This ’lag phase1
represents the time taken for drug disintegration, dissolution and 
transit of drug from stomach to the small intestine (Wagner, 1961).
The small intestine on account of its large absorptive surface area 
is optimal for rapid passive drug absorption (Stenlake, 1979)* In 
addition to the factors influencing mucosal transport, other determinants 
of gastrointestinal drug absorption include, dissolution of the dosage 
form, gastrointestinal motility, splanchnic circulation, and competing 
reactions in the gastrointestinal wall and lumen (Moffat, 1978;
Houston and Wood, 1980; Rowland and Tozer, 1980).
PULMONARY ABSORPTION
Pulmonary absorption occurs by passive diffusion across a lipid- 
pore type membrane (Burton, jet al.., 197^). Volatile lipid—soluble 
general anaesthetics are rapidly absorbed following inhalation on 
account of the very large surface area and rich blood supply of the 
lungs (Stenlake, 1979)*
TOPICAL ABSORPTION
Drug absorption through the human skin may occur by diffusion 
through the hair follicles, sweat ducts or stratum corneum. The large 
surface area of the stratum corneum, however, makes it the most 
important of these routes for cutaneous drug absorption (Moffat, 1978; 
Stenlake, 1979).
The rate of absorption through the skin is much slower than that 
through the gastrointestinal tract. Absorption through the skin is 
enhanced by skin damage or abrasion or vehicles such as dime thy lsulphoxide 
(Parke, 1981; Stenlake, 1979).
DISPOSITION
DRUG DISTRIBUTION
Following absorption, a drug usually traverses one or more 
biological membranes in order to reach its ultimate site of action 
(Levine, 1978). Definite information on drug distribution requires 
the measurement of a drug in various tissues; data of such kind has 
been obtained in animals, but is lacking in human pharmacology, for 
obvious practical reasons (Rowland and Tozer, 1980).
The principal determinants of tissue drug distribution are:
1. vascular perfusion of the tissue,
2. permeability of tissue to the drug,
3. tissue binding of drug, and the
4. physicochemical characteristics of the drug.
(Rowland, 1978; Levine, 1978; Rowland and Tozer, 1980; Stenlake, 1979).
PERFUSION: The rate of tissue perfusion becomes a limiting factor
influencing distribution when the tissue membranes present no barrier to 
diffusion e.g. diffusion of drugs across the muscle capillary walls 
(Rowland, and Tozer, 1980). All other factors remaining the same, well 
perfused tissues will take up a drug more rapidly than poorly perfused 
tissues. The net rate of drug uptake by a tissue is related to the 
tissue blood flow, Q, by the following equation:
Net rate of uptake = Q. (C^ — C y ) ------- 8
where and Cy are the arterial and venous drug concentrations 
respectively.
PERMEABILITY: The capillary endothelium except in the brain, does not
restrict drug distribution. Most drugs whether ionized or not; diffuse
into the interstitial fluid. Water—soluble drugs readily traverse 
the capillary wall, but at rates slower than trans-capillary transport 
of lipophilic drugs. Relatively small hydrophilic molecules traverse 
the capillary wall at rates directly proportional to their concentration 
gradients. The driving force for drug transport across the capillary 
wall for large hydrophilic molecules appears to be the hydrostatic 
pressure of the blood. Hepatic and renal capillaries present less of a 
barrier to the transfer of molecules than do capillaries elsewhere; 
this is in keeping with the fmiction of these organs (Levine, 1978).
Blood-Brain barrier: The inability of some compounds to enter the
cerebrospinal fluid (C.S.F.) from the blood has led to the concept of 
the blood-brain and blood-C.S.F. barriers. These barriers behave as 
typical lipoprotein membranes allowing drug penetration by simple 
diffusion. The rate of drug penetration into the C.S.F. and brain 
is thus dependent on the lipophilicity and lipid/water partition 
coefficients of the drug (Brodie and Hogben, 1957). Certain areas of 
the brain are, however, permeable also to polar molecules, e.g. the 
pituitary, area postrema and the inter-columnar tubercle. Filtration 
across the arachnoid villi represents the main process whereby both 
lipophilic and hydrophilic substances are extruded from the C.S.F.
Some ionized species may be removed by active transport from the C.S.F. 
through the choroidal epithelium,
Feto—Maternal barrier: The placenta acts as a barrier for compounds 
with molecular weights over 1000. Relatively smaller molecules, e.g. 
drugs, can however cross the placenta by simple diffusion. Placental 
drug transfer also depends on the lipophilicity of the drug. Highly 
ionized drugs, e.g. suxamethonium (Moya and Kvisselgard, 196l) and
tubocurarine (Crawford and Gardiner, 1956) are usually poorly 
transferred. Weak acidic and basic drugs are transported in 
accordance with the lipid solubility of the unionized species.
Most drugs readily cross the placenta, including morphine, narlophine, 
tetracyclines and barbiturates.
DRUG BINDING:
Plasma protein binding: Acidic drugs commonly bind to albumin and
basic drugs to 0C -a.cid glycoprotein and lipoproteins (Reidenberg et al.f 
1971; Reidenberg and Affrime, 1973> Fremstad et al., 1976; Piafsky,
1980). Protein drug binding is a reversible process with very rapid 
rates of association and dissociation; the bound drug is in equilibrium
with the free drug. The determinants of protein binding are:
1. the affinity of the protein for the drug,
2. the concentration of protein, and
3. the concentration of drug.
The unbound drug fraction (fu) is related to the unbound protein (p)
by the equation,
f =       9
u 1 + K.p y
where K is the association constant (Rowland and Tozer, 1980).
Only a small fraction of the available sites on a protein are 
usually occupied at therapeutic drug concentrations. Neutral molecules 
may bind to protein by van der Waals forces, hydrophobic interactions 
and/or hydrogen bonding (Eik~nes, fet al,, 195^)« The plasma 
concentration of a binding protein may be decreased by disease, e.g. 
decrease in plasma albumin in chronic liver disease.
Binding of a drug to plasma protein limits the concentration of
the drug in the tissues and at its site of action. Only the unbound 
drug is in equilibrium across the capillary wall (Borga al., 1969; 
Houghton et al.t 1975). Glomerular filtration is also limited by 
plasma protein binding ( Kunin et al.t 1959)«
The rates of metabolism of certain drugs also appear to be related to the 
extent of plasma protein binding (Wiseman and Nelson, 196*1). Increased 
pla sma protein binding may result in decreased drug elimination (e.g. 
warfarin and phenytoin). However, increased plasma protein binding 
may also be associated with a decrease in drug elimination half-life, 
e.g. propranolol (Evans et al., 1973)*
Tissue drug binding: Many drugs accumulate in muscle and other cells
in higher concentration than they occur in the extracellular fluid.
Drug accumulation in tissue may be due to active transport; more 
commonly it is due to binding of drug to tissue macromolecules, and 
proteins, phospholipids and nucleoproteins have been implicated in 
tissue drug binding.
Neutral drugs, with high lipid solubility, may be extensively 
deposited in body fat. For example, as much as 70$ of the dose of 
intravenous thiopental may be present in the body fat three hours 
post-dosage. Plasma pH is an important determinant of fat storage 
of ionizable fat-soluble drugs (Stenlake, 1979)*
METABOLISM
Many drugs are lipid-soluble, weak organic acids or bases that 
are not readily eliminated from the body. To be excreted they must 
be transformed into more polar compounds which are less lipid soluble, 
more readily ionized at physiologic pH, less protein bound and less
able to penetrate cell membranes. In a few instances non-enzymic 
reactions play a significant role in drug degradation in the body 
(Testa, 1982; Morikawa, _et ajL, 1979)* For example, thalidomide 
and alkylating agents are degraded by spontaneous interaction with 
water and other endogenous components. For the majority of drugs, 
however, enzymic drug transformation is the major pathway of metabolism 
with non-enzymic drug degradation playing a minor role. Enzymic 
drug transformation may be conveniently classified into:
1. Functionalization reactions (Phase I or bio-transformation) 
involving oxidation, reduction, hydration or hydrolysis and
2. Conjugation reactions (Phase II or synthetic processes) in 
which an endogenous molecule is combined with a xenobiotic 
or its metabolite (Parke, 1981; Caldwell, 1980).
The portals of entry and exit of the body, the lungs, kidneys, 
skin and gastrointestinal mucosa may be involved in drug metabolism.
These extrahepatic sites may transform drugs and other Xenobiotics to 
either inactive or active forms prior to their entry into the circulation 
and access to the target tissue (Vainio and Hietanen, 1980). However, 
the principal sites of drug metabolism are the liver and the gastro­
intestinal tract with lesser activity in the lungs, kidneys and skin. 
Intestinal drug metabolism is similar to that of the liver but with 
lower rates of activity (Parke, 1981).
HEPATIC BIOTRANSFORMATION: Liver microsomes contain several enzyme
systems including two electron transport systems, an NADPH-linked 
cytochrome P-450 and an NADH-linked cytochrome b^ system. (Omura, 
et al., 1965;)« . . . The cytochrome P-450 system is a
heterogeneous system containing an unknown number of closely related 
enzymes that catalyse the oxidation of steroids, fatty acids and a large
number of structurally diverse xenobiotics (Lu, e_t al.., 1976; Coon, 1978 
Trager, 1980). The. function of the cytochrome b^ system is not well 
understood; it appears to be involved in fatty acid desaturation and 
may play an auxiliary role in reactions catalysed by cytochrome P-450 
(Trager, 1980).
The cytochrome P-450 system: The mixed-function oxidase system consists
of the terminal oxygen transferase, cytochrome P-450, coupled to 
cytochrome P-450 reductase (a flavoprotein containing both FAD and FMN), 
and linked to a source of electrons from NADPH. Cytochrome P-450 
catalyses the insertion of an atom of oxygen from molecular oxygen 
into the substrate (e.g. a drug); the other atom of oxygen interacts 
with two protons and two electrons to give a molecule of water (see 
fig. l.l), hence the name mixed function oxidase (Mason, 1957) or 
monooxygenase (Hayaishi, 1966). Cytochrome P-450 is present in 
tissues usually in the low-spin state (a 6-ligand complex); the 
sixth ligand is a hydroxyl group of an amino acid (or the nitrogen 
of a histidine moiety) of the apoenzyme. In normal mixed function 
oxidase reactions, following binding of cytochrome P-450 with its 
substrate, the enzyme changes from the low spin form to a high spin 
state (5 ligands, with the hydroxyl ligand broken), resulting in a 
conformation change in the enzyme and activation of oxygen prior to its 
insertion into the substrate (Parke, 1981). Oxidative reactions 
catalysed by the microsomal mixed function oxidase system include 
aliphatic and aromatic hydroxylation, epoxidation, N-oxidation, 
S-oxidation, dealkylation and deamination (Parke, 1981). The 
cytochrome P-450 system may also catalyse the reduction of certain 
xenobiotics (Harada and Omura, 1980).
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Multiple forms of cytochrome P-450 with different substrate 
selectivity have recently been identified (Comai and Gaylor, 1973;
Ryan, et al.., 1975; 1979; 1981; Ryan and Levin, 1981; Botelho, et at., 
1979; Haugen, jst aJL«, 1975)* The multiple forms of cytochrome P-450 
are regarded as isoenzymes or enzyme variants with overlapping 
substrate specificities (Parke, 1981).
Hepatic mixed function oxidation may result in:
1. detoxication with subsequent excretion of the resulting 
metabolites; this is by far the most common and is largely 
responsible for the termination of drug action.
2. conversion of a drug to a pharmacologically active metabolite, 
e.g. conversion of imipramine to desipramine.
3. conversion of a drug or xenobiotic into a reactive intermediate 
reactive intermediates are highly reactive chemical species, 
generally electrophiles such as carbonium ions, carbenes and 
free radicals, which react readily with glutathione, tissue 
proteins, RNA. or DNA. with resulting tissue damage.
4. Ligand-complex formation in which a metabolic intermediate 
binds tightly to the haem iron of cytochrome P-450 with 
inhibition of mono-oxygenase activity, displacement of 
cytochrome P-450 activity by cytochrome P-448 activity, lipid 
peroxidation and denaturation and degradation of cytochrome 
P-450 (Franklin, 1977; Parke, 1981; Obrebska, et aj.., 1980).
Other mono-oxygenase systems: Other mono-oxygenase systems are also
present in the hepatic endoplasmic reticulum, e.g. flavoprotein 
oxidase, which catalyses sulphoxidation (Hajjar and Hodgson, 1980) and, 
together with cytochrome P-448, also catalyses the N-oxidation of
tertiary amines (Hlavica and Htillsman, 1979).
HEPATIC PHASE II REACTIONS: The possession of a suitable functional
group is essential for conjugation of xenobiotics. Most conjugation 
reactions utilize hydroxyl, amino, heterocyclic nitrogen and thiol 
functional groups* In certain cases, chemically unstable species such 
as epoxides, arene oxides and carbonium ions may take part in synthetic 
reactions (Caldwell, 1980). Endogenous molecules participating in 
synthetic reactions include sugars, e,g, glucuronic acid (Marsh and 
Levy, 1963; Smith and Williams, 1966), amino acids, e.g. glycine 
(Williams, 1963), acids, e.g. acetic acid (Parke, 1968; Williams, 1967), 
alkyl groups (methyl) and miscellaneous substances such as glutathione 
(Parke, 1981),
Synthetic reactions can be divided into two types:
1. An activated endogenous molecule, commonly a nucleotide 
(e.g. uridine diphospho glucuronic acid) reacts with the 
xenobiotic or its metabolite. This is the commonest reaction 
sequence in xenobiotic conjugation reactions.
2. An endogenous molecule reacts with a high energy intermediate 
of a xenobiotic or its metabolite (Williams, 1967).
The enzyme catalysing the conjugation reactions are located in the 
endoplasmic reticulum (UDP-glucuronyl transferases) or in the cytosol 
(sulpho-transferases, glutathione-S-transferases, methyl transferases) 
(Parke, 1981). The vast majority of drug conjugation reactions result 
in inactive, more hydrophilic, more polar and more readily excreted 
drug products. In some synthetic reactions, however, the conjugated 
species may possess pharmacological activity, that may be even greater 
than that of the parent drug (Caldwell, 1980).
EXCRETION
Drugs are eliminated from the body unchanged or following metabolism 
to more polar, less lipid soluble metabolites. The principal organ for 
drug and metabolite elimination is usually the kidney. Drugs and their 
metabolites may also be excreted via the bile, faeces, expired air, milk, 
sweat, saliva and other secretions.
RENAL EXCRETION: Renal excretion of drugs involves three processes,
glomerular filtration, active tubular secretion and tubular reabsorption.
The appearance of drug in the urine is the net result of these processes:
Rate of glomerular Rate of tubular Rate of tubular 
Rate of excretion = Filtration + secretion —• reabsorption
(Rowland and Tozer, 1980).
Glomerular Filtration: Glomerular filtration produces an ultra-filtrate
of the blood plasma. Only drug dissolved in plasma water is filtered; 
drug bound to macromolecules or blood cells does not cross the glomerular 
membrane. The drug concentration of the glomerular filtrate is thus 
identical to that of plasma water. .
Active tubular secretion: The secretory processes of the renal tubule
are located mainly in the proximal tubule. Separate mechanisms appear 
to be responsible for tubular secretion of organic acids (e.g. penicillin, 
probenecid and glucuronides) and organic bases (e.g. procaine and 
hexamethonium). Both systems however lack high specificity; each 
system is responsible for the transport of organic ions of similar 
charge.
Substances transported by the same system compete with each other, 
e.g. probenecid reduces the tubular secretion of penicillin (Gibaldi, 1977).
Renal tubular reabsorption: Tubular reabsorption of the majority of
drugs from the lumen of the renal tubules is by passive diffusion. The 
degree of reabsorption is thus dependent on the physico-chemical 
characteristics of the drug, e.g. lipophilicity, ionization and 
molecular weight. Tubular reabsorption is also influenced by urine 
flow rate and urine pH (Bochner et al., 1973; Beckett and Wilkinson,
1965; Wilkinson and Beckett, 1968; Beckett et al., 1969; Rowland and 
Beckett, 1966; Kostenbauder et al., 1962; Dettli, jet a_l., 1967; Cohen 
and Pocelinko, 1973). Active tubular reabsorption has also been 
implicated in the reabsorption of certain xenobiotics from the renal 
tubular lumen (jusko and Levy, 1970).
BILIARY AND FAECAL EXCRETION: Many drugs and their metabolites are
excreted by the liver into the bile. The main determinants of biliary 
excretion is molecular weight and polarity (Smith, 1973). Based on 
correlation between molecular weight and the extent of biliary excretion, 
a threshold molecular weight has been determined for organic ion 
excretion. Compounds with molecular weights below this threshold are only 
minimally excreted into the bile (less than 10$ of dose). The threshold 
molecular weight varies with species and ranges from about 325 in rats 
to about 500 in man (Millburn et al., 1967; Millburn, 1970; 1976;
Hirorn ejfc aJL., 1972a; 1972b).
Possession of a polar group, or a potentially ionizable group, 
e.g. carboxylic acid or quarternary ammonium group is a pre-requisite for 
extensive biliary excretion (Smith, 1973). The possession of such a 
group confers hydrophilic properties to a compound at physiological pH.
The presence of one or more water-soluble sugar residues confers similar 
hydrophilic characteristics to drugs or other xenobiotics which lack 
anionic or cationic groups (e.g. cardiac glycosides).
The mechanisms whereby substances undergoing biliary excretion 
are transferred from the hepatic sinusoids into the biliary canaliculi 
are improperly understood. Some compounds have a bile/plasma ratio of 
about 1 (Class A compounds); others have bile/plasma ratios greater 
than 1, usually between 10 and 1000 (Class B compounds); others still 
have ratios of less than 1 (Class C compounds) (Bra:uer, 1959). Class 
B compounds are excreted into the bile by carrier mediated active 
transport systems,of which five types are recognised:
1. organic anion system
2. organic cation system
3* neutral system
4. bile acid system, and
5. a system for metals.
(Alpert, jst aJL., 1969; Paumgartner and Reicher, 1975; 1976; Klassen 1976) 
Interaction of biliary micelles present in the bile may also be partly 
responsible for the high bile/plasma ratios (Vonk, et .al*, 1977).
Enterohepatic circulation: Drug or metabolite conjugates excreted in the
bile may be hydrolysed by enzymes in the bile (f3-glucuronidase, sulphatase 
or by enzymes of the intestinal microflora. The freed drug or metabolite, 
if sufficiently lipophilic and noil-polar, may be reabsorbed, transported 
to the liver, re-conjugated and re-excreted into the bile. Drugs which 
behave this way are said to undergo enterohepatic circulation (e.g. 
digoxin and imipramine).
OTHER ROUTES OF EXCRETION: Many volatile anaesthetics are excreted in
the expired air (Parke, 1968; 1981). Traces of many drugs and other 
xenobiotics are excreted in the sweat; an anti-leprosy drug, ditophal 
is, however, extensively excreted in the sweat of human subjects in 
amounts which equal or exceed the combined total faecal and urinary
excretion (Ellard, jit al., 1965). Drugs may also be excreted in the 
saliva, e.g. sulphonamides and penicillins (Brodie, et al_., 1958; 
Borzelleca and Cherrick, 1965), gastric juice, e.g. nicotine and 
quinine (Anderson, et al., 1965; Shore, et al,, 1957) and milk 
e.g. alcohol, morphine and barbiturates (Knowles, 1965). Some drugs, 
e.g. lithium are actively secreted into the saliva (Groth, et al.,
1974). During lactation clinically important drug concentrations in 
the infants blood may result from maternal ingestion of drugs 
(O’Brien, 1974; Brandt, 1976; Yurchak and Jusko, 1976).
PHARMACOKINETICS
Pharmacokinetics is the study of the time course of absorption, 
distribution, metabolism and excretion in terms of model systems, of 
rate constants and of apparent volume of distribution, (Curry, 1980).
In recent years this basically mathematical science has paid increasing 
attention to physiological principles (Atkinson and Kushner, 1979)> in 
an attempt to predict possible alteration in drug disposition that 
might occur in the presence of disease or concurrent drug therapy 
(Shand, 1978). In clinical pharmacokinetics, pharmacokinetic principles 
are applied in the treatment of patients in the clinical setting: the
principles are applied in designing loading and maintenance doses, and 
determining dosing intervals for individual patients, and making dosage 
adjustments in patients with renal, cardiac or hepatic failure, etc.
The ultimate aim is to prevent drug toxicity whilst ensuring the 
maintenance of effective therapeutic drug concentrations (Gibaldi, 
and Levy, 1976a; 1976b; Jusko, 1973a; Levy, 197^).
SINGLE DOSE PHARMACOKINETICS.
ONE COMPARTMENT OPEN MODEL:
Rapid intravascular administration: In certain circumstances it is
Dose
BODY
el ^ELIMINATION
sufficient to regard a drug (x) as uniformly distributed in a single
body compartment instantaneously (Wagner and Northam, 1967), following
rapid intravenous administration,, The rate of drug elimination 
dX(— - ) is then given by the equation:
^  - -K Xdt " el X
where X is the amount of drug in the body and K^‘ is the elimination 
rate constant. Integration of the above equation yields:
v v - K i tX = X e el o
-------  11
where Xq is the dose of drug administered, and X is the amount of drug 
in the body at time, t. Normally, it is the concentration of the drug 
in the plasma, serum or blood that is measured rather than the total 
amount of drug in the body. Expressing equation (ll) in terms of plasma
drug concentrations yields:
C = C e~Kel * o 12
where C is the concentration at time = 0 and C is the concentration 
o
at time = t.
Such a mono-exponential expression is seen with the rapid distribution 
and onset of action of neuro-muscular blocking agents. Equation ( 12) 
can be transformed logarithmically into,
13
or log C = log C - K , t ------- 14& & o el
In C = In C - K , t -------o el
2.303
Thus a plot of log G against t is linear with a slope of -
2.303
and an intercept at zero time of log Cq (Gibaldi, 1977; Clark and 
Smith, 1981).
The volume of distribution this is equal to the volume of body
water -which the compartment is estimated to contain if the drug were 
uniformly distributed between the compartment and plasma in the same 
concentration. The distribution volume is termed, apparent volume of 
distribution, for it seldom corresponds to physiological or anatomical 
body spaces. For a drug which is distributed according to a one 
compartment model, the apparent volume of distribution by area
(Vd[area.]> is given *y>
VW  x = X d (area) o ---------15
iEfficE
where AUC is the area under the plasma concentration-time curve 
following drug administration and b, is the elimination rate 
constant (Shargel and Yu, 1980; Stenlake, 1979). The distribution 
volume is, however, often calculated from the concentration change 
resulting from the administration of a known amount of a drug; thus
V. = X° --------- 16
d c"o
where Cq is the concentration of drug in plasma at zero time, obtained 
by extrapolating the log C-time curve back to zero (Atkinson, et al. t 
1979; Clark and Smith, 1981). The distribution volume may also be 
calculated from the concentration change resulting from the removal of 
a measurable amount of drug by haemodialysis (Atkinson, et al^i 1976),
Determinants of include, the physicochemical characteristics 
of the drug (e.g. lipophilicity), plasma and tissue drug binding, and
body fat and water content. Drugs which are highly plasma-protein 
bound (e.g. thyroxine) have small Vj values, whilst highly lipid- 
soluble drugs and drugs with high tissue binding give high values.
Elimination half—life ): this is a commonly used indicator of the
rapidity with which a drug is eliminated from the body. It is the 
time required for the drug concentration to fall to one half its value 
at some previous time. From equation (3)» if V/Cq = \ then
- 11 K , •-= In -|
2 e -*-
ti = In 2
2 K lel
*1 = M 2  --------- !7
2 K iel
Extravascular drug administration: In the case of extravascular
Kel ^ ELIMINATION
administration, an additional phase is incorporated into the one 
compartment model to account for the phase of absorption. The drug
concentration in the plasma is then given by:
-K , t _ K t
C = Be - Ae 9 --------- 18
where A = intercept of monoexponential absorption slope with the
ordinate.
B = intercept of back-extrapolated monoexponential elimination
slope with the ordinate
= absorption rate constant.
K , = elimination rate constant, 
el
C = concentration at time, t,
(Ritschel, 1980).
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Intravenous administration: following rapid intravenous injection of
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a drug, the plasma drug level may fall in a biphasic fashion; the 
initial rapid decline (distribution phase) is mainly due to drug 
distribution from the central compartment to the peripheral compartment 
with drug elimination playing a minor role. The later slow decline 
(elimination phase) is mainly due to drug elimination (metabolism and 
excretion) from the body with distribution playing a minor role. Such 
biphasic plasma concentration-time curve fits the equation:
C = B e "pt + A e “at ..........- 19
where
C = the plasma drug concentration
B = intercept of back-extrapolated monoexponential elimination 
line with the ordinate
(3 = overall elimination (slow disposition) rate constant (equal 
to slope of elimination line).
A = intercept of monoexponential C C —line with the ordinate.
CC = slope of the mono exponential distribution line (distribution 
rate constant)
OC and (3 are hybrid rate constants: thus
+ P = Kl,2 + K2,l + Kel 
" K2,l Kel
and
(Gibaldi and Perrier, 1975; Ritschel, 1980).
Extravascular drug administration: an additional phase is added
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to the two compartment system to account for absorption from the
extravascular site, thus:
20
where Cq = drug concentration at zero time ( Cq = A + B) and 
Kq = absorption rate constant.
MULTICOMPARTMENT MODELS:
In most instances, the one and two compartment, intravascular and 
extravascular models provide adequate kinetic description of 
experimental data. In a few instances more complex models may be 
necessary for the kinetic treatment of experimental data.
FLIP-FLOP MODEL:
In flip-flop model, the rate of absorption or the micro-constants 
of distribution are slower than the rate of elimination. Flip-flop 
models may be observed following topical and rectal drug administration 
or following intramuscular injection of procaine penicillin (Ritschel,
1980).
MULTIPLE DOSE PHARMACOKINETICS
Most drugs are administered in a repetitive or chronic manner.
Drug disposition studies are, however, often conducted with single doses
with little further regard to the effect of multiple doses. Single 
dose kinetic data may not always he valid in the multiple dosage 
situation, since saturation of metabolic or excretory processes 
and changes in drug distribution or disease during multiple dosing, 
may significantly alter the pharmacokinetics of the drug (Portman,
1970). Thus the importance of multiple dose pharmacokinetics cannot 
be over-emphasised.
ONE COMPARTMENT OPEN MODEL:
Intravenous infusion: zero order intravenous infusion can be considered
as multiple dosing with infinitely small dosing intervals. It takes 
about 5 biological half-lives until a steady state drug concentration 
is reached. The drug concentration time curve declines exponentially 
after cessation of infusion.
During the infusion, the drug concentration is given by the equation: 
R K , t s
c - r f ,  < 1 - e' ) -------------21d el
and following termination of infusion the drug concentration is given by:
* 0 / - K f»i \ " ^ e l  ^  ~  ^ i ^C = rr-—  (1 - e el 1 ) e 61 1 ---------- 22
d el
where C = drug concentration in blood, plasma or serum.
R = zero order infusion rate
0
V, = volume of distribution 
d
K , = overall elimination rate constant 
el
t. = time of infusion
1
t = total time since start of infusion 
Intravascular multiple dose: following repetitive intravascular drug
administration, the maximum drug concentration is given by the equation:
max 1 - e 23
and the minimum drug concentration is given by:
C .m m
C e-K *'To________
1 -K elT1 - e
= C e max
- K e,T
----------2k
where Cmax
m m
Kel
maximum drug concentration in plasma, serum or blood 
minimum drug concentration in bloody plasma or serum 
initial drug concentration after first dose 
overall elimination rate constant and 
dosing interval.
The average (mean) drug concentration (C ) in blood, plasma or serum
S S
in multiple dosing is given by
ss V , K t T d el
25
where X
V,
dose size
volume of distribution.
Bxtravascular multiple dose: following repetitive extravascular drug
administration the maximum (C ) and minimum (C . ) drug concentrations' max7 ' m m 7 ^
in the blood, plasma or serum are given by:
max
C .m m
C- K o a
K -K , a el
C K o a
K -K , a el
k T  el m a *
1 - e
-ke,T
1 “K !T 1 — e el
k T  e“ a m a x
I - e-kaT
i “K T ,1 - e a
------ 26
---------27
where Kg = absorption rate constant and
t = time to reach maximum concentration after n doses, 
max
Fluctuation at steady state: The extent of fluctuation at steady state
between C and C . is given by the drugs half-life and the dosing 
max m m
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interval. The longer the biological half-life and the shorter the
dosing interval, the less will be the fluctuation. The degree of
fluctuation may be estimated from the following equation:
$ Fluctuation ~ (l - e ^elT ) x 100 — — - - — 28
(Ritschel, 1980). Dosing at intervals longer than the tjL will
2
result in more fluctuation in the plasma drug levels. Drug 
accummulation is likely if the dosing interval is less than 1.4 times 
the half-life (Roger and Spector, 19.81).
CLEARANCE CONCEPTS
The half-life of a drug is a poor index of the efficiency of drug 
elimination. In certain situations altered drug elimination is not well 
accounted for by changes in the drug elimination half-life (Shand, 1978). 
A more sensitive index of drug elimination is the systemic clearance 
(Rawlins, 1980).
SYSTEMIC CLEARANCE: This is the volume of plasma cleared of drug from
the systemic circulation per unit time. The systemic clearance (Cl )s
is estimated from the systemic venous blood as:
Cl ~ ■ — — — — 29
s AUC y
where X = dose of drug administered
F = fraction of dose reaching systemic circulation 
AUC = area under the plasma concentration time curve
For intravascular drug administration F = 1. For extravascular 
administration F may be less than 1 (Wilkinson and Shand, 1975).
Systemic clearance is the sum of both metabolic and excretory clearance 
processes: thus
cls = C1M + clll + ch  +   50
where CL, = metabolic clearance 
M
Cl^ = renal clearance
C1T = pulmonary clearance (Rawlins, 1980).
Jj
The major routes of drug elimination are however hepatic metabolism
and renal excretion. Thus for drugs eliminated mainly by renal
excretion
C1S ~  C1E
and for drugs eliminated mainly by hepatic metabolism 
Clg —  C1M (Rawlins, 1979).
Hepatic clearance C1^.:.I£ average drug concentration of both
hepatic arterial and portal blood, then the rate at which the liver removes 
drug is given by:
Rate of drug removal (r ) = Q^ . (C^ - Cy) --------- 31
where Qjj = combined hepatic blood flow and
Cy = drug concentration in hepatic venous blood
But, Cl„ = Rate of drug elimination (r ), where Cl„ = hepatic clearance
CA
Thus, C1H = Qh (Ca  - Cy) __________32
CA
Thus hepatic clearance is the product of hepatic blood flow and hepatic 
extraction ratio, (C^ - Vy)» Hepatic intrinsic clearance (81^) is the
volume of liver water cleared of drug per unit time (Branch et al., 197.3): 
it is independent of blood flow and is related to the rate of drug 
removal by:
R = Cl. x f --------- 331 F
where fp = free drug concentration in the liver or free drug
concentration in the hepatic venous blood (Rowland et al.,
1975).
Also f = C x where iL is fraction of unbound drug
r V B B
in the blood: equation (33) can be written as;
R = Cl. x C x f ------  34
1 V jj
Expressing Cli:j in terms of intrinsic clearance gives
C1i x fB
c 1h  - Q    35^ x B
The model described by equation (35) is the venous equilibration 
model (Rowland, jet jal., 1973). The model provides adequate description 
of the effects of altered blood flow on propranolol (Branch, ejfc al,., 1973) 
and lignocaWfce elimination in the perfused rat livei’ (Shand, et al.,
1975> Pang and Rowland, 1977 ). When intrinsic clearance is low 
compared to blood flow, then the hepatic extraction is low, thus:
C1H —  C1i X fB ----------- 36
and drug elimination is determined by hepatic enzyme activity and plasma
protein binding. For drugs with high intrinsic hepatic clearance,
equation (35) reduces to:
C1H—  QH ------------- 37
and hepatic clearance is dependent on blood flow. Flow dependent drugs
include propranolol (Branch, et aj.*, 1973; Evans, et al,, 1975) and 
lignocaine (Stenson ej; al.., 1971): altered binding has little effect on
hepatic clearance (non-restrictive elimination). From equation (36) 
increasing plasma protein binding will decrease the hepatic clearance of 
poorly extracted drugs and decreasing binding will have the opposite effect 
(Restrictive elimination), e.g. warfarin (Levy and Yacobi, 197;*) and 
phenytoin (Gugler et al., 1975).
Oral drug clearance: Drugs may be metabolised in the gastrointestinal
tract during absorption, or by the liver before they reach the systemic 
circulation. This phenomenon is termed presystemic or first pass 
metabolism (Harris and Riegelman, 1969; Routledge and Shand, 1979).
The apparent oral drug clearance (CiQ) is given by
Cl = i L l f l D<> ----------   38
0 QE
where E = hepatic extraction ratio
D = oral dose of a drug o
1-E = the fraction of dose reaching the systemic circulation.
Significant presystemic drug elimination occurs with relatively highly 
extracted drugs like propranolol (Shand and Ilangno, 1972) and lignocaine 
(Boyes al., 197i), but not with poorly extracted drugs like antipyrine,
tolbutamide and warfarin .(Aidreason and Vesell, 197^), Liver blood flow may
be estimated from the pharmacokinetic data of highly extracted drugs 
(Wilkinson and Shand, 1975); thus imipramine (Gram and Christenson, 1975)» 
alprenolol (Alvan et al., 1977) and propranolol (Kornhauser et al., 1978) 
have all been used to estimate liver blood flow.
Renal Clearance (Cl^): when the rate of renal drug elimination is
proportional to drug concentration in the plasma (c), then
rate of renal elimination == Cl^ x C  -----------39
Also
rate of elimination = urine flow rate x urine drug concentration
Cl^ = urine flow rate x urine drug concentration--------- ^0
C
Determinants of renal drug clearance include plasma drug concentration 
(jusko and Levy, 1970), urine flow rate (Bochner, et aJL., 1973)> urine 
pH (Beckett and Wilkinson, et ajL., 19^5) and plasma protein binding 
(Kunin, et aJL., 1959)*
NON-LINEAR PHARMACOKINETICS
The pharmacokinetics of a drug are said to be non-linear when plasma 
drug concentration-time curve after different doses are not identical when 
normalized for dose. Non-linear pharmacokinetics may be due to saturation
of blood and tissue binding sites (McNamara, jet a_l., 1979), saturation 
of drug metabolising enzymes (Lundquist and Wolthers, 1958; Gerber and 
Wagner, 1972; Christophidis, et al,, 1978; Rawlins, ejt aj.., 1977;
Shand and Rangno, 1972), auto-induction of hepatic enzymes (Levy, et al., 
1979), end-product (metabolites) inhibition of hepatic enzymes (Perrier, 
et al,, 1973) and saturation of carrier transport systems. The 
clearance of drugs which exhibit non-linear kinetics can often be 
described using the Michaelis-Menten equation (Ritschel, 1980;
Atkinson and Shaw, 1973; Ludden, jet jal., 1977) (see equations5 - l)
FACTORS INFLUENCING DRUG DISPOSITION AND 
PHARMACOKINETICS IN HUMANS
The administration of the same dose of drug to a population of 
individuals may result in variation in plasma drug concentrations 
(Collste, 1976; Lund, 1973; Hammer, et al., 1967;
Rawlins, et al,, 197^). The observed variation in drug concentrations 
may be due to differences in drug absorption and bioavailability (McMartin
and Simpson, 1971? Prescot, 197^), drug distribution (Saraiva et al.,
1977), metabolism (Sjoqvist, et a_l., 1967), excretion (Smith and Rawlins,
1973), which may in turn be due to genetic ( Sloan,jet al_, 1978;
Vesell, 1980) and non genetic (Gibaldi, 1977; Wilkinson and Schenker,
1976) influences.
GENETIC FACTORS.
Large inter-individual variations in drug disposition and hence drug 
responses are under genetic control (Vesell, 1979)# Two forms of 
genetically controlled variation in drug disposition are recognised:
1. Polygenic variation and
2, Monogenic variation or genetic polymorphism
POLYGENIC VARIATION: The response to most drugs in a population follows
a normal distribution. This type of variation is thought to be the 
result of interaction of polygenic genes with environmental factors. 
Polygenic control of the disappearance from the plasma of bishydroxy- 
coumarin, phenylbutazone and nortriptyline have been reported 
(Motulsky, 1964; Whittaker and Evans, 1970; Asberg et al., 1971).
Identical twins showed close agreement in the rate of metabolism of 
nortriptyline (Alexanderson, ejb aJL., 1969), phenylbutazone, diconmarol, 
antipyrine and alcohol (Vesell, ejt al.., 1971), whereas fraternal twins 
did not. This is by far the commonest mode of pharmacogenetic drug 
variation.
GENETIC POLYMORPHISM: In genetic polymorphism, pharmacogenetic variation
exhibits a bimodal (discontinuous) distribution, and is under the control 
of a single gene. Polymorphic variation is a relatively rare phenomenon 
(idle and Smith, 1979).
Polymorphic acetylation of drugs: Hepatic drug acetylation is under
polymorphic control (Evans ejfc a^., i960). Acetylation is catalysed by 
the non-microsoma1 enzyme, N-acetyl transferase. Familial studies 
indicate that slow acetylators are homozygotis for an autosomal- 
recessive gene and that rapid acetylators are either homozygotts or 
heterozygous for a dominant gene (Weber, 1973). The prevalence of the 
slow aeetylator phenotype in the U.K. is about 55$ (Farah, et aJL., 1977).
In general, Caucasians, Africans and Mexicans are equally or slightly 
more likely to be slow than rapid acetylators. The Japanese, Chinese 
and Eskimos on the other hand are more likely to be rapid acetylators 
(Ellard, 1976). Aeetylator status does not appear to change with age 
(Farah, et .al., 1977). Drugs exhibiting polymorphic acetylation 
include isoniazid (Evans et £l,, I960), procarinamide (Davies ejfc jLL., 1975;
Gibson ejt ail., 1975? Du Souich and Erill, 1976), hydral.lazine (Evans 
and White, 1964; ), dapsono (Gelber al,, 1971)
and sulpliamethazine (Evans and White, 1964). Slow acetylators are 
more likely to experience adverse reactions to the above drugs than 
rapid acetylators (Smith and Rawlins, 1973; Woosley, ejt jYL, 1977;
Das, ejt aL, 1973; Perry, jet al., 1970;).
Polymorphic drug oxidation: Several examples of genetic polymorphism
of drug oxidation in man have been reported in recent years. Among 
these are phenformin (idle and Islam, 1981.), sparteine (Eichelbaum, 
e_t £l., 1979), guanoxan and phenacetin (Sloan, ejt _al., 1978), 
debrisoquine (Majigpub, et ail., 1977; Evans, ejt aJL., 1980;
Wool-house, ejt aj.., 1979; Mbanefo, jet ajL., 1980) and nortriptyline 
(Bei’tilsson, jet al^, 1981). In most populations studied, about 
1 - 9$ of individuals were identified by their relative difficulty 
in effecting the oxidation of these drugs. Polymorphic drug oxidation 
is under single gene control (Sloan ejt a_l., 1978; Majhgoub, ejt a_l., 1977).
Debrisoquine is extensively metabolized to its 4-hydroxylated 
metabolite in most individuals (Extensive metabolizer phenotype E.M.); 
in a few individuals (Poor metabolizer phenotype P.M.), about 5 - 9$ 
of Caucacians in the U.K., there was impaired drug oxidation.
Debrisoquine oxidation is controlled by a single autosomal gene which 
is allemorphic, the two alleles being D^ (high debrisoquine hydroxy- 
lation) and D^ (low debrisoquine hydroxylation). Individuals homozygous 
for the D^ have impaired ability to effect oxidation of the other drugs 
listed above besides debrisoquine (Sloan, ejt ajL•, 1978; Sloan, jet el,, 1981
HShah, ejfc aj.., 1980). Heterozygotes and D homozygotes are extensive 
metabolizers of these drugs. Individuals with impaired drug oxidation 
hove a higher likelihood of drug accumulation to toxic levels (Ritchie, 
et ajL., 1980 ).
Other drugs whose metabolism exhibit genetic polymorphism include 
succinylcholine, hydrolysed by plasma pseudocholinesterase (Karlow, 1973) 
and tolbutamide metabolised by microsomal oxidation (Roger and Spector,. 1981
AGE AND DEVELOPMENT
Nafcillin and ampicillin are better absorbed in the newborn than 
in adults (Silveiro and Poole, 1973; Jusko, 1973b). Absorption of 
digoxin in newborns and adults were, however, similar (Hermandez, 1969).
The rate and extent of gastrointestinal absorption of lorazepam 
(Gieeriblatt, et al., 1979a; Greenblatt, et al., 1979b) and paracetamol 
(acetaminophen) (Divol.l, ejfc aj.., 1982) were not significantly altered 
in the elderly.
Drugs may have higher volumes of distribution (Wettrell, 197b) or 
lower volumes of distribution (Kauffman, ejfc _al., 1972) in infants than 
adults. In the elderly, hydrophilic and relatively lipid-insoluble 
drugs, e.g. paracetamol and antipyrine have lower values (Divoll, 
et al., 1982; Greenblatt, 1982a). In contrast, lipophilic drugs are 
extensively distributed in the elderly (Macklon, ejfc al.., 1980;
Greenblatt, et al., 1980; Klotz, ejfc ajL., 1975; Ochs, et ale, 1981;
Nation, e_fc al,., 1977).
Drug oxidation and hj'droxylation occur early, but at a reduced 
rate, in the neonate. Glucuronidation of drugs and drug metabolites
is perhaps the most inefficient drug Metabolic pathway during early 
development and may take longest bo mature (Done, et al., 1977).
In the elderly, drug biotransformation (mainly hydroxylation and 
dealkylation) may be impaired (O’malley, _et al,, 1971; Greenblatt, 
et aj.., 1982a)« Ageing appears to have a much smaller effect on 
drug glucuronidation (Greenblatt, et al., 1982b).
Most drugs have prolonged half-lives during early infancy.
Drugs whose excretion depends on active renal tubular secretion are 
most likely to be affected in this respect (Done, ejfc al^ ., 1977). 
Drugs like digoxin (Ewy, _et a_L., 19^9) and procainamide (Reidenberg, 
et al,, 1980) whose total clearance involves renal excretion, partly 
or entirely, show a decline in total clearance in proportion to the 
age-dependent decrease in glomerular filtration.
DISEASE
Several disease states are known to influence drug disposition 
and pharmacokinetics. Thus the plasma elimination ha.lf—life of 
antipyrine was dependent on thyroid status (Eichelbaum, ejfc a^., 197^) 
Patients with congestive heart failure had higher stead3^ state 
lignocaine levels and decreased lignocaine clearance than patients 
without heart failure (Zito and Reid, 1978). The volumes of 
distribution of quinidine, lignocaine and procainamide were decreased 
in patients with congestive heart failure (Crouthamel, 1975; Kessler, 
ejfc al^, 197^5 Thompson, ejj al., 1975; Kock-Weser and Klein, 1971). 
The plasma concentration of disopyramide ’was lowei’ in patients with 
recent myocardial infarction than in normal volunteers (ilelt, jrfc al. 
1979-)* Reduced bioavailability of metolazone (diuretic) in cardiac 
failure patients has also been reported (Tilstone, et al., 197/i).
Drugs that are highly extracted by the liver may be poorly 
extracted in patients with reduced hepatic function (Pessayre, e t a 1.,
1978). Both acute and chronic liver disease may significantly alter 
the disposition of poorly extracted drugs: thus the presence of
liver disease was associated with reduced plasma clearance of diazepam 
(Klotz, ejfc al0, 1975), chlordiazepoxide (Roberts, ejt ajL., 1978), 
hexobarbital, (Breimer, ejfc ajL,, 1975), amobarbital (Mawer, et al,, 1972) 
and theophylline (Mangione, ejfc al., 1978), In patients with acute 
paracetamol-induced hepatic necrosis, there was prolongation of anti-= 
pyrine half-life with return to normal within one to three weeks later 
(Forrest, ejfc jal., 1974). Gross impairment of antipyrine and lignocaine 
metabolism were noted in a young female patient with chronic active 
hepatitis (Adjepon-Yamoah, jrt jal., 1974). It is not always possible, 
however, to generalise about the possible effects of liver dysfunction 
on drug disposition: significant impairment in the capacity of the
liver to metabolise drugs is difficult to assess clinically (Prescott,
1979). Moreover-* patients with advanced liver disease are capable of 
metabolizing drugs normally. Impairment of drug metabolizing
capacity is, however, likely in cases where the plasma albumin is low
and the prothrombin time is prolonged (Prescott, 1979; Wilkinson and
Schenker, 197&3).
In renal failure, the renal clearance of a drug is generally 
decreased in proportion to the reduction in creatinine clearance. The 
half-life of drugs excreted mostly unchanged is not greatly prolonged 
until the creatinine clearance falls below 40 - 50 ml/min; below a 
clearance of 20 ml/min, however, a disproportionate and alarming 
increase in the drug elimination half-life occurs (Prescott, 1979). 
Generally, the elimination of drugs, metabolised largely by oxidation 
and glucuronidation, is not affected by the uraemic state (Prescott, 1979).
Drug reduction and acetylation may, however, be slowed in uraemic 
patients (Reidenherg, 1977« ; Gibson, et al., 1977) and the oxidative 
metabolism of phenytoin appears enhanced in uraemia (Odar-Cederlof 
and Borga, 1974). Decreased binding of acidic drugs to plasma protein 
occurs in renal failure (Reidenberg, 1976; 1977; Erill, ^t aty, 1980); 
renal transplantation, but not dialysis, increased the impaired plasma 
protein binding of acidic drugs (Afrime, _et £l,, 1979).
SEX
The volume of distribution of diazepam (Greenblatt, r^fc a_l., 1980), 
desmethyldiazepam (Allen, _et jal., 1980) and chlordiazepoxide (Greenblatt, 
et al., 1977) were larger in females than males: sex differences in
protein binding may be partly responsible for the human female-male 
differences in drug distribution (Greenblatt, et al,, 1977). Clearance 
of diazepam was, however, identical in both sexes (Greenblatt, et al.,
1980) though decreased diazepam clearance in females (Macleod, et al., 
1979) has also been reported.
OBESITY
Theoptylline (Gal, et al., 1978), digoxin (Ewy, et al,, 1971), 
gentamycin and tobramycin (Schwartz, e_fc aj^ ., 1978; 3louin, et al.,
1979) are distributed to a lesser extent in overweight subjects.
The volume of distribution of antipyrine (distribution limited to 
body water) and diazepam (extensively distributed in body fat) were 
higher in obese subjects than in normal age- and sex—matched controls 
(Abernethy, ejfc aty, 1981); drug elimination half-lives were also 
longer in obese subjects than in controls, and clearance of both 
drugs were decreased by obesity.
SMOKING
Antipyrine clearance was higher in normal healthy male smokers 
(under 40 years old) than in non-smokers; no such difference was 
seen in men over 40 years of age. The enzyme-inducing effect of 
smoking appears to diminish with increasing age (Wood, et al., 1979).
Mean blood concentrations after oral propranolol were 200$ higher in 
non-smokers than in smokers; no difference, however, was observed in 
the elimination half-life of propranolol between the two groups 
(Vestal, ejt ajL., 1979).
ALCOHOL
In normal subjects, ethanol (greater than 800 mg/l and maintained 
for 8 hr) increased the plasma unchanged-diazepan A.U C but decreased 
the A,U C for N-desmethyl~diazepam, indicating inhibition of the 
N-desmethylation of diazepam. In contrast, there was no significant 
change in the metabolism of oxazepam (which is mainly metabolised by 
glucuronidation) after a single dose of ethanol (Sellers, _et al., 1980). 
Phenytoin elimination half-life was shorter in alcoholics during withdrawal 
than in control subjects (Kater, 19^9); the increased phenytoin 
clearance during alcohol withdrawal was due to increased drug 
metabolism, secondary to alcohol-induced hepatic enzyme-induction (Sandor 
et al., 1981).
DRUG INTERACTIONS
Most drug interactions are kinetic in origin (Rawlins, 1977). A 
drug may inhibit the absorption of another drug, (e.g. decreased 
absorption of tetracycline by ferrous sulphate; Neuvonen and Turakka,
1974), or enhance the absorption of another drug, (e.g. enhanced
absorption of dicoumarol by magnesium hydroxide; Ambre and Fisher, 1973). 
Avidly protein-bound drugs may be displaced from their binding sites 
with increase in pharmacological effect (e.g. displacement of warfarin 
from albumin by trichloroacetic acid; Sellers and Koch-Weser, 1971).
Drug interaction may result in stimulation of metabolism, (e.g. 
stimulation of the metabolism of warfarin (Udall, 1975) and dicoumarol 
(Goss and Dickhaus ) by phenobarbitone,,or inhibition of metabolism 
(e.g. inhibition of the metabolism of phenytoin, dicoumarol and 
tolbutamide by chloramphenicol; Christensen and Skovsted, 1 9 6 9 ).
Altered drug excretion may also follow during interaction, (e.g. 
decreased renal excretion of quinidine by acetozolamide and sodium 
bicarbonate (Gerhardt, ejfc al.*, 1969)).
FOOD AND STARVATION
Food may reduce or increase the bio-availability of drugs 
(Toothtaker and Welling, 1980). Increasing the ratio of protein to 
carbohydrate or fat in the Riet (Anderson, et aty, 1979) or feeding 
cabbage and brussel sprouts (Pantuck et al., 1979) stimulated drug 
metabolism in humans. Inhibition of drug metabolism occurs on the 
continuous ingestion of food containing theobromine or methyl xanthines, . 
i.e. coffee, tea, cocoa (Drouillard, ejt ajL., 1978). No major changes, in 
drug metabolism occurred in obese subjects when they were put on a daily 
diet of 15g carbohydrate for 10 - 14 days (Reidenberg and Vesell, 1975; 
Reidenberg, 1977b); renal excretion of sulfisoxazole was decreased by 
fasting,
OCCUPATION
Workers in insecticide plants had shorter plasma elimination half- 
lives of antipyrine (Kalmodin, jit ajL., 1969) and phenylbutazone (Poland,
et al., 1970; Kalmodin-Hedman, 1973)* The elimination half-life of 
warfarin in residents in anaesthesia were prolonged after 4 months 
exposure to volatile anaesthetic agents in the operating theatre 
(Ghoneim, al., 1975)*
PERHEXILINE
CHEMISTRY
Perhexiline is a chemical analogue of hexadylamine, a compound 
with anti-anginal and coronary haemodynamic effects (Lewis, et al.,
1962; Rowe, .et aJ.., 1963). Perhexiline is 2-(2,'2-dicyclohexyl ethyl) 
piperidine (see Figure 1*2), It is marketed as perhexiline maleate 
(Pexid) tablets: the maleate salt is a white crystalline powder,
readily soluble in ethanol and methanol but only slightly soluble in 
water and physiological saline. It melts at 185.5 - 191°C (Hudak, 
et a3L., 1970; Rowe, et al., 1970; Causa and Perri, 1971; Hudak, et al., 
1973)* Perhexiline exists in two isomeric forms, (+) perhexiline and 
(-) perhexiline, and Pexid is a racemic mixture of the two isomers.
DISPOSITION AND PHARMACOKINETICS 
ABSORPTION:
14Following oral administration of 6mg/kg of C-perhexiline base to
14 /Charles River rats, 53$ of C label was absorbed in two hours (Leeson,
jit ajL., 1969a). Absorption of an oral dose of perhexiline in both rats
and dogs was found to be both rapid and complete (Leeson, et ajL., 1972;
Wright, £t a^ L., 1970). In human volunteers absorption was nearly complete
twelve hours after an oral dose of perhexiline: the amount of drug
absorbed, however, varied from 66$ to greater than 85$ of the administered
dose (Wright, et al., 1973). In five patients with severe angina pectoris
and impairment of left ventricular function, the rate of absorption 
of drug from oral pexid tablets varied considerably (Horowitz, et al.,
1981).
DISTRIBUTION:
14Plasma levels of C were maximal one hour after an oral dose of 
■^C-perhexiline (6 mg/kg) to rats: low plasma levels of radioactivity
were, however, sustained for seven hours. Maximum tissue levels of 
radioactivity occurred 2 - 3  hours after dosage; the lung, liver and
kidney had the highest specific activity, and significant levels of
14 /C were detected in the heart, spleen and skeletal muscle (Leeson, jet al.
1969a). In dogs receiving 1.0 mg/kg "^C-perhexiline maleate intravenously
the highest arterial plasma levels 10 pg/ml (expressed in terms of
perhexiline maleate) occurred within 3 0 seconds; a rapid decline of
arterial plasma levels then occurred so that at one hour the levels
were only 0.3 fig/ml. Arterial blood and plasma levels were greater than
venous levels. The mean tissue to plasma ratios of perhexiline
concentrations at one hour post dosage were liver 35.4, ventricle 9*8,
auricle 6.0, lung 4.2, spleen 7.6 and kidney 9.0. Protein binding studies
on tissue homogenates demonstrated a high degree of binding of perhexiline
(Leeson, et _al., 1969b).
14Oral administration of C-perhexiline to rats and dogs resulted 
in exceedingly low plasma perhexiline levels; of the drug related 
materials in the plasma of rats after a single oral dose of perhexiline, 
12$ or less represented the unchanged drug (Wright, 1970). The highest 
level of perhexiline in the gastro-intestinal tract, after oral 
administration of ^C-perhexiline maleate (6 mg/kg), occurred one hour 
after dosing in Sprague Dawley rats. Significant levels of monohydroxy
and dihydroxy-perhexilines were already present in the gastrointestinal 
tract, one hour after drug administration; the highest level of these 
metabolites of perhexiline in the gastrointestinal tract occurred 
6 hours post dosage. Of the tissues studied, the liver had the 
highest concentration of perhexiline, monohydroxy-perhexiline and 
dihydroxy-perhexiline. Despite large increases in the dose of 
perhexiline, the plasma levels of perhexiline remained low (Leeson, 
et al,, 1972).
14In man, following oral dosage with C-perhexiline, (100 mg 
perhexiline maleate) plasma levels of the drug-related materials were 
very low, being less than 0.3 pg/ml (Wright, 1970). In four male 
subjects given 98 - 103 of oral ^C-perhexiline maleate (0.2 |ic/mg 
perhexiline maleate) the blood and plasma concentrations of radio­
activity were again very low during the first 24 hours after drug 
administration; in all instances the radioactivity in the blood did 
not exceed the equivalent of 210 ng/ml of perhexiline; however, the 
chemical form of in the blood was not determined (Wright, et al,, 
1973). In a multiple dose study five healthy adult male volunteers 
were given 200 mg b,i,d. of perhexiline for 14 days followed by ingestion 
of a single dose of 100 mg ^C-perhexiline maleate in (20 (ici) sdlujbion 
on the fifteenth day, with cessation of drug administration. In four 
subjects, plasma and whole blood radioactivity was maximal at 12 hours; 
in the fifth subject the maximum blood and plasma concentration occurred 
at 6 hours. The concentration of radioactivity was generally higher in 
the plasma than in whole blood (Wright, et al,, 1973)*
In five elderly patients with severe angina pectoris and defective 
left ventricular function there was a time lag of 1,0 to 2.5 hours 
before the appearance of detectable concentrations of perhexiline in
the plasma after oral perhexiline (150 and 300 mg on two separate 
occasions). Peak concentrations of unchanged drug occurred 3 - 6  hours 
after drug ingestion in four subjects. In the fifth patient, peak 
plasma concentrations occurred 12 hours after the 150 mg dose and 
18 hours after the 300 mg dose study (Horowitz, et al,, 1981).
ELIMINATION:
No ^ C 0 o was detected in the expired air when 6 mg/kg of
■^C-perhexiline was administered to rats orally. In 24 hours,
35 - 50$ of the administered "^C was present in the bile; excretion of
. 14
radioactivity was mainly through the faeces, with 84$ of C-dose
being excreted in the faeces and urine in 24 hours. After an oral
14 / / \ < 14dose of C-perhexiline (1 mg/kg) 81 - 93$ of C was excreted in
_  14
24 hours; in six days 94 + 4$ of C was recovered in the excreta.
In contrast, 31 “ 65$ and 80 - 93$ of the administered dose of ^ C
was excreted in 24 hours and 7 days respectively after an equivalent 
dose of intravenous ^C-perhexiline (Leeson, jet a^., 1969a)# After 
both the oral and intravenous studies faecal excretion of radioactivity 
was three times that of urinary excretion.
■^C appeared in the urine of the dog 4 hours after an oral dose
(6 rag/kg) of ^4C-perhexiline. In 5 days 33 - 4$ of the dose was
excreted in the urine and 54 - 4$ in the faeces. No unchanged 
perhexiline was found in bile., urine or faeces (Leeson, eit al.., 1969h). 
Unchanged perhexiline was, however, detected in the liver, lung, spleen, 
kidney, brain and gastrointestinal tract of the rat (Leeson, et al,, 1972).
Hydroxylation of the cyclohexyl rings represented the main route of 
biotransformation of perhexiline in the rat (Leeson, jet _al., 1969*0#
The major portion of the metabolites of perhexiline from rat and dog bile
urine and faeces, corresponded to synthetic reference compounds with 
4-hydroxyl groups in one or both cyclohexane rings (Wright, 1970)
(see Fig. 1.2). Perhexiline is rapidly metabolised in the rat.
One hour after oral administration of perhexiline, significant 
amounts of monohydroxy- and dihydroxy-perhexilines were already 
present in the gastrointestinal tract with peak metabolite levels 
occurring 6 hours later. Monohydroxy- and dihydroxy-perhexilines 
were present in several tissues examined, with the liver containing 
the highest concentration of these metabolites. Monohydroxy- and 
dihydroxy- perhexilines were detected in the urine although the 
unchanged drug was not. Despite large increases in the dose of 
perhexiline given to the rats, the plasma levels of perhexiline remained 
low (Leeson, et aJL*, 1972), and of the drug-related materials in the 
plasma, only 12$ or less was in the form of the unchanged drug, the 
rest probably representing hydroxylated perhexiline metabolites 
(Wright, 1970).
In man, excretion of perhexiline materials after an oral dosage
14with ' C-perhexiline was more or less equally via the urine and 
faeces. As in rats and dogs, the excretion of ^ C  after a single 
dose was almost exclusively in th'e form of metabolites, though the 
extent of conjugation was less. The major metabolites of perhexiline 
in man were also identical to the synthetic mono- and di-hydroxylated 
perhexilines; unchanged perhexiline could not be identified in the 
urine or faeces (Wright, 1970; Wright, et £l*> 1973)*
The major circulating metabolite of perhexiline in man has been shown 
to originate from cis-hydroxylation at the para position of.one of the 
cyclohexyl rings (Fig. 1.3) > trans-hydroxylation at the para position 
of the cyclohexyl ring gives rise to the second most abundant circulating
metabolite (Wright, et al,, 1973). Further hydroxylation of the two 
isomeric monohydroxyl perhexilines, occurs; the resulting dihydroxy- 
perhexilines have been detected in human urine following oral 
administration of perhexiline (Wright, et jal., 1973; Singlas, jet al.,,
1978). Conjugation of the monohydroxy- and dihydroxy-perhexilines 
have also been reported; glucuronide conjugates of perhexiline 
metabolites have been identified in human urine (Wright, ejt al^, 1973)*
There appears to be individual variation in the excretion of
perhexiline metabolites in man. Wright (1970) reported that in most
subjects the excretion half-lives of radioactivity in the urine after 
14an oral dose of C-perhexilme varied from 2 - 5  days. In another 
single dose study,, the excretion half-life of • perhexiline-relatedhnaierials 
in the urine varied between 3 and 3.4 days from three male volunteers; 
a fourth volunteer had much longer retention of perhexiline with a half- 
life of 12.3 days. In a multiple dose study (in which 5 men received 200 
b.i.d. of perhexiline maleate daily for 14 days followed by 20 jiCi of 
■^C-perhexiline maleate on the fifteenth day) the cumulative recovery 
of radioactivity was 83 - 96$ for 4 subjects who excreted the material 
more rapidly and 65$ for the subject with the slowest excretion rate.
The major route of excretion was the urine with the excretion of 
radioactivity in the urine being greater than twice the faecal excretion. 
Excretion of radioactivity in the urine did not seem to depend on the 
urine volume (Wright, jrt aJL., 1973).
The plasma elimination half-life of perhexiline 24 hours after drug 
administration appeared to be "dose ‘ dependent, increasing from 
about 18 hours after 150 mg to 24 hours after 300 mg dose of Pexid 
tablets. The areas under the plasma concentration-time curve for 300 mg: 
150 mg dose was 5.3 : 1 implying non-linear pharmacokinetics. Thus
h.1
hepatic hydroxylation of perhexiline could be saturable with variable 
systemic availability of oral perhexiline (Horowitz, ejfc aJ., 1981).
MECHANISM OF ACTION
The molecular mechanisms of action of perhexiline are improperly 
understood. There is evidence that it acts as a calcium antagonist 
(Fleckenstein-Grun, et .al*, 1978; Vaughan-Williams, 1980). Calcium 
antagonists inhibit excitation-contraction coupling in myocardial and 
smooth muscle by blocking the transmembrane calcium transport, resulting 
in decreased myocardial contractility and vasodilation (Fleckenstein,
1977)* In isolated guinea pig hearts, perhexiline increased coronary 
blood flow at doses that had little effect on contractility (Klaus and 
Guttler, 1978). Perhexiline-induced increases in coronary blood flow 
has been observed in dogs (Cho, ejfc ajl*, 1969; Rowe, et al*, 1970;
Hudak, jet al^, 1969; 1970; 1973; Daniell,
et al., 1977). Both negative (Hudak et al,, 1970; 1973; Cho, ejb aJL*, 1970; 
Klaus and Guttler, 1978) and positive inotropic effects of the drug has 
been observed.
A decrease in transmitter release during sympathetic stimulation
i
may be involved in the mechanism of action of perhexiline (Daniell, et al., 
1979; Michelin, jejfc al^ *, 1980). Automaticity of ventricular pace makers 
is reduced by perhexiline with little effect on atrial pacemakers in 
in vitro preparations (Ten Eick and Singer, 1973)* The drug may act 
directly on the sino-atrial node to produce bradycardia (Matsuo, et al.t 
1970). Ventricular extra systoles are reduced by perhexiline (Drake, 
et al,, 1973; Sukerman, 1973; Pickering and Goulding, 1978; Schweizer, 1978)
Perhexiline appears to shift available 0^ from fat oxidation to
carbohydrate oxidation (Kluppel, et al., 1976; Klassen, ejt aj.., 1978;
Calm, et£l., 1978; Pepine, ejt£l., 1974t; Luccioni, .et al.., 1978; 
Vaughan-Williams, 1980).
THE MECHANISM OF ANTI ANGINA EFFECT
Several studies have confirmed the efficacy of perhexiline maleate 
in the prophylaxis of angina pectoris (Hrschleifer, 1969; Burns-Cox, 
et jal., 1971; Lyon, et al., 1971; Grupp, ejfc j3l., 19‘70; Winsor, 1970; 
Symposium, 1973; Lockhart and Masheter, 1976; Caponetto, ejfc jal., 1977).
The anti anginal action of perhexiline may be due to
(1) a decrease in exercise-induced tachycardia (Morledge, jet al.., 1973; 
Cherchi, jet aJL., 1973; Morgan and Rees, 1973; Afzal-Mir and 
Kafetazkis, 1978).
(2) a redistribution of coronary blood flow from normal areas
towards ischaemic areas of myocardium (Klassen, et al., 1978; 1979).
(3) a reduction in cardiac dysrhythmia (Drake, jat jal., 1973;
Sukerman, 1973)
(4) and better utilization of Og end lactate by the myocardium 
(Vaughan-Williams, 1980).
OTHER PHARMACOLOGICAL ACTIONS IN MAN
Resting heart rates (Hamdam, et a^., 1973; Libretti, jit al,, 1973) 
and blood pressure (Pilcher, 1978) were not affected by perhexiline.
Systolic blood pressure rose during exercise in angina patients on 
perhexiline (Niedberger, jit al,, 1978). In patients on perhexiline 
therapy (400 mg for 10 days), there was an increase in the left 
ventricular work index at rest with reduction on cardiac pacing (Pepine, 
ejt ajL., 1974). The secretion of insulin was both delayed and increased 
by perhexiline after oral glucose (Luccioni, et a3L., 1978). Perhexiline 
has a diuretic effect (Hutcheon, 1969; Czerwinski, jet aJL., 1973;
Hoekengaet al., 1973; Gitlin and Nellen, 1973) and may be partly 
responsible for the weight loss associated with perhexiline therapy.
(Datey, jet al., 1973; Kim, 1975; Burns-Cox, et al., 1971).
PERHEXILINE TOXICITY
Perhexiline has negligible acute toxicity in laboratory animals 
(Causa and Perri, 1971). Despite earlier reports to the contrary, it is 
now well appreciated that the drug is associated with significant side 
effects.
MINOR SIDE EFFECTS: The commonest subjective side effect of perhexiline
is dizziness (Armstrong, 1973; Garson, et al., 1973; Git'lin and Nelien, .1973) 
Other common adverse effects of perhexiline are nausea and vomiting 
(Oliveira, et al., 1973), headache (Cherchi, et al., 1973), coarse tremor 
(Datey, et al., 1973), gait disorders (Hoekenga, et al., 1973) and 
giddiness (Datey, et al., 1973)# Other less common side effects include 
syncope (Garson, et al., 1973), delirium (Burns-Cox, et al., 1971), 
nervousness (Hoekenga, et al., 1973),
metallic taste in the mouth, gingivitis (Datey, et al., 1973), abdominal 
pain and dyspepsia (Hamdam, et al., 1973), palpitations (Armstrong, 1973), 
dysuria (Howard and Rees, 1976), paraesthsiae (Pilcher, et al., 1973), 
impotence (L!Hermitte, et al., 1976),| lethargy (Datey, et al., 1973) and 
weight loss (Datey, et al., 1973).
With the exception of impotence, the subjective side-effects of 
perhexiline appear early during the initial phase of treatment. The side- 
effects are usually transient; 69$ of side-effects lasted for a month or less 
(Lockhart and Masheter,1976); and rarely required perhexiline therapy to be 
stopped. Some side-effects persist throughout the duration of perhexiline 
therapy (Burns-Cox, et al., 1971), and may be severe enough to warrant 
discontinuation of treatment (Hoekenga, et al., 1973; Datey, et al., 1973; 
Howard and Rees, 1976).
Many (20 - 50$) patients, on perhexiline will experience one or more 
of the mild side-effects mentioned above (Marcheix and Ponsonnaille, 1979; 
Horowitz and Mashford, 1979; Afzal-Mi:r and Kafetzakis^l978).More side- 
effects occurred with a dose of 400 mg daily than with 200 mg daily of 
perhexiline maleate (Lockhart and Masheter, 1976). .No adverse effect was 
experienced by patients on 100 mg perhexiline twice daily despite efficacy 
in prophylaxis against angina (Horgan,et al.t 1981).
MAJOR SIDE EFFECTS:
Hepato-toxicity: Patients on "perhexiline may have transient or persistent
rises in serum aminotransferases and alkaline phosphatase levels (Garson, 
et <al., 1973; Afzal-Mir and Kafetzakis, 1978). Rises in lactate 
dehydrogenase (Morledge, 1973), isocitrate dehydrogenase (Lockhart and 
Masheter, 1976) and 5 '-nucleotidase (Howard and Rees, 1976) have also 
been reported. The perhexiline induced aberration in liver enzymes appears 
to be dose-related (Pilcher, et al., 1973;Hbrgan, jit .al., 1981).
Several cases of perhexiline-induced hepatic injury have been reported 
following chronic administration of the drug (Kopelman and Morgan, 1977; 
Stentiford, 1977; Bonnet, et aJ., 1978). Liver biopsies in patients with 
perhexiline-induced toxicity reveal an increase in the number of kuppfer 
cells, centrilobular necrosis with inflammatory cells, Mallory's bodies, 
nuclear vacuolation, increased number of nucleoli, swollen hepatocytes 
with foamy cytoplasm, distortion of liver architecture with fibrosis of 
portal tracts and septa and heavy inflammatory infiltration of portal 
tracts and septa (Beaugrande, et al., 1977; 1978; Lageron, et al.. 1977a; 
1977b; McDonald, 1977; Herne, et £l., 1976; Lewis, et ajL., 1979; Forbes, 
jit aJL., 1979; Pessayre, et al., 1979; Poupon, et al., 1980). Six cases 
of perhexiline-induced JLiver damage which ended fatally have been reported 
in recent years (Beaugrande, jit aJL., 1977 (one case); Bonnet, j^ jj.£l., 1978
(one case); Lewis, et al,, 1979 (one case); Pessayre, et al., 1979 
(two cases) and Forbes, et al., 1979 (one case)).
Peripheral neuropathy: A number of clinicians have reported perhexiline-
induced polyneuropathy in some patients on long term perhexiline therapy 
(Abaza, et al., 1973; Bourrat, et al., 1975; Bousser, et al., 1976; 
L'Hermitte, et al., 1976; Pollet, et al., 1977; Mussini, et al., 1977). 
Two-thirds of patients on perhexiline, without clinical evidence of 
neuropathy, had electrophysiological changes in the peripheral nerves 
(Sebille, 1978). The cerebrospinal fluid in patients with perhexiline- 
induced neuropathy is usually abnormal with a raised protein content but 
no pleocytosis (Said, 1978; Herne, ejfc ad., 1976). Papilloedema has also 
been reported in association with perhexiline therapy (Stephens, et al.,
1978; Tomlinson, and Rosenthal, 1977; Hutchinson,et al., 1978;
Atkinson, et al., 1980). Papilloedema may be associated with raised 
(Poisson, et al., 1977) or normal (Hutchinson, et al., 1978) intracranial 
pressure,
Perhexiline-induced neuropathy is characterised by loss of myelinated 
fibres, segmental demyelination, Wallerian degeneration and membrane-bound 
lysosomal (complex lipids) inclusions in Schwann cells (Pollet, et al^ ., 1977; 
L'Hermitte, et al,, 1976; Mussini, et al.. 1977). An increase in peripheral 
nerve ganglioside has also been reported; other glycolipids are not, 
however, affected (Pollet, et al., 1977).
Hypoglycaemia: Another serious but rare side effect of perhexiline is
hypoglycaemia (Feldman, 197^ =5 Roger, et a^., 1975; Sudre, ut aj.., 1976; 
Dally, et al., 1977). The hypoglycaemic effect of perhexiline may be due 
to an abnormality in insulin secretion (Luccioni, jrfc jal., 1978). A series 
of hypoglycaemic episodes have been reported in a 67 year old man on 
concurrent perhexiline and pindolol therapy (Bourmayan, et al,, 1978).
Mechanism of hepato- and neuro-toxicity; The mechanism of perhexiline- 
related toxicity in humans is far from clear. Histochemical studies on 
liver and to a lesser extent, peripheral nerves have demonstrated various 
storage disorders involving gangliosides, triglycerides fatty acids, 
phospholipids and glycogen (Lageron, et .al., 1977a; 1977b; Beaugrand. , 
et a_l., 1978; Pollet, et al,, 1977; L'Hermitte, jet a^ L., 1976; Mussini, 
et al., 1977). Polymorphous lysosomal inclusions have also been identified 
in liver and nervous tissue.
Perhexiline-induced polymorphous membranous inclusions (Myeloid bodies) 
have also been observed in both human and animal tissue (Fardeau, et al., 
1979; Lullmann and Lullmann-Ranch, 1978; Jung and Suzuki, 1978; Hauw, 
jrt jal., 1980; Le Gall, ejfc aJL., 1980). A decrease in the activity of 
hepatic glucose 6-phosphatase and (3-glucuronidase, with an increase in 
activity of 3-phospho-glyceraldehyde dehydrogenase and lactate dehydrogenase 
have also been reported (Lageron, jit .al., 1977a). High doses of perhexiline 
increased hepatic total phospholipids and gangliosides in the rat whilst 
decreasing pulmonary gangliosides (Hoenig and Werner, 1979). Exposure of 
fibroblasts to high concentrations of perhexiline resulted in marked 
increases in phospholipids, cholesterol and gangliosides (Hauw, et al., 
1980); clinically relevant perhexiline concentrations also produced an 
increase in cholesterol and phospholipid content of human fibroblast 
cultures (Albouz, jJt'j*l., 1981).
Myeloid body formation can be induced by a wide variety of drugs.
Some twenty other drugs are known to induce these lysosomal changes 
(Lullmann et al., 1975); such drugs are all amphiphilic compounds with 
both a cationic nitrogen and an apolar ring system with a tendency to 
accumulate in tissues. Cationic hydrophobic drugs are thought to bind to 
the anionic hydrophobic phospholipds; the drug-phospholipid interaction
impairs normal lysosomal digestion of phospholipids resulting in 
phospholipid accumulation within the lysosomes (Lullman, et aj.., 1975).
The binding of drugs, such as perhexiline, to phospholipids could alter 
the fluidity of the membrane (Lenaz, et al., 1978) resulting in either an 
increased turnover of membrane components associated with impairment of 
lysosomal degradation processes or an alteration of membrane recycling 
(Dean, 1977). As ganglioside GM is the natural substrate of |3-galactosidase, 
the perhexiline-induced decrease in the activity of this enzyme could be 
responsible for the perhexiline-induced intralysosomal storage of 
gangliosides (Le Gall, .et aJL., 1980).
In 1976, L'Hermitte suggested that the neuropathy associated with 
perhexiline therapy might be the result of individual susceptibility, 
possibly related to some genetic metabolic disorder (L'Hermitte, et al., 1976 
Patients with perhexiline-induced neuropathy were subsequently show to have 
slower hepatic metabolism of the drug, longer plasma elimination half-life 
and higher plasma perhexiline concentrations than non-neuropathic patients 
(Singlas, et jal*, 1978). Recently, Shah and associates (Shah, jit ajl*, 1982) 
showed that 20 patients with perhexiline neuropathy but not 14 non- 
neuropathic patients had impaired ability to metabolize debrisoquine.
They suggested the use of routine drug oxidation phenotyping as a 
screening procedure to identify patients at risk of developing perhexiline- 
induced neuropathy on prolonged drug administration.
RESEARCH OBJECTIVE
Perhexiline and its metabolites in biological fluids do not lend 
themselves readily to quantitative determination and analysis. This 
difficulty in drug and metabolite determination is to a large measure 
responsible for the paucity of published pharmacokinetic data on
perhexiline. For rational and proper use of a drug detailed kinetic data 
in patients, especially repeat-dose kinetics, must he available. For 
this, a sensitive and specific, non-isotopic quantitative method of 
analysis is essential. In the case of perhexiline, individual 
differences in kinetic handling of the drug appears to be a major factor 
in the development of drug-induced toxicity, but this was missed in the 
early clinical studies because of the lack of a suitable quantitative 
analytical method and consequently, a lack of human pharmacokinetic data. 
This project therefore aims at;
1. developing a sensitive analytical method for determining per­
hexiline and its major metabolites, which will be suitable for 
both single-dose and multiple-dose pharmacokinetic studies in 
humans,
2. studying the nature of perhexiline pharmacokinetics in human 
volunteers,
3. investigating the stereo-selective kinetics and metabolism of 
perhexiline in humans, and
4. characterization of the hepatic microsomal hydroxylation of 
perhexiline in animals, in vitro.
Figure 
1,2. 
Structures 
of 
perhexiline 
and 
its 
hydroxylated 
metabolites
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Figure 
1.3* 
Monohydroxy-perhexiline 
Diastereomers
CHAPTER 2
THE DEVELOPMENT OF A HIGH 
PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD
INTRODUCTION
Pre-column off-line derivatiza.tion, a standard procedure in gas 
liquid chromatography (g.l.c.), is finding increasing application in 
high performance liquid chromatography (h.p.l.c.). The reasons for 
derivative formation are:
1. to allow the chromatography of compounds which can not
otherwise he analysed by chromatographic methods,
2. to enhance the resolution of compounds, and
3. to improve detection sensitivity or selectivity (jupille, 1979)*
A common approach in derivative formation is to attach a chromophore to 
suitable fimetienable..gr0up4 iu th£compound' pf interest.- The ultra-violet 
absorbance of the resultant derivative is then measured with a ultra­
violet absorbance detector at an appropriate wavelength.
Perhexiline and its metabolites do not possess natural absorption 
characteristics in either the visible or ultra violet regions and are, 
therefore, not suited for analysis by ultra violet spectrophotometrie 
detection following liquid chromatography. Fortunately, however, 
perhexiline and its related compounds do possess a reactive functional 
secondary amine nitrogen (Fig. 2.1) to which a substituted aromatic 
chromophore could be attached, thereby rendering them detectable with 
ultra violet monitors. Perhaps the most common ultra violet tagging 
amine group reagent is l-fluoro-2,4-dinitrobenzene (FDNB) (Cox, 1973)*
In the present study, an h.p.l.c. method for measuring perhexiline and 
its major monohydroxy metabolites in human blood plasma and urine was 
developed using N-dinitrophenyl derivatives of the drug and its metabolites.
MATERIALS AND METHODS
MATERIALS AND REAGENTS
Test tubes (25 ml) with Teflon-lined screw caps (Soveril, France) 
and 10 ml pear-shaped flasks (Quickfit, U.K.) were used* All aqueous 
solutions were prepared with de-ionized water that had been passed 
through a 0.45 U filter. Reagent grade FDNB, disodium tetraborate 
(borax) and sodium hydroxide (B.D.H. Chemicals Ltd., U.K.), diethyl 
ether (analytical grade, May and Baker, U.K.) and cyclohexane 
(analytical grade, B.D.H. Chemicals Ltd., U.K.) were purchased.
Methanol (analytical grade, James Burrough, U.K.) was passed through 
a 0.45 ^ filter before use. Perhexiline, cis- and trans-monohydroxy- 
perhexiline mixture (l:4), trans-monohydroxy-perhexiline, an internal 
standard (2-[2-cyclohexenyl, 2-cyclohexyl ethyl] piperidine hydro­
chloride) and hexadiline (see Fig. 2.1) were gifts from the Merrell 
National Laboratories, Cincinnati, Ohio, U.S.A.
EQUIPMENT
A chromatographic system incorporating a Gradient Master, 2 
Constametric I pumps (Laboratory Data Control [L.D.C.] U.S.A.) a 
Rheodyne syringe loading sample injector with a 100 p.1 sample loop 
(Model 7120, Rheodyne, U.S.A.) and a Spectromonitor III (L.D.C., U.S.A.) 
set at 360 nm was used in the analysis. Chromatographic separation of 
samples was achieved using a C^g reverse phase Spherisorb S5 0DS 
column (250 x 4.6 mm) (Phase Separation, U.K.).
METHOD
DERIVATIZATION AND ANALYSIS OF PERHEXILINE BY H.P.L.C.:
A series of duplicate tubes were set up containing 0 to 10 pg/ml
of perhexiline base in a total volume of 2 ml. Derivatization of 
perhexiline in the aqueous samples was carried out by the method described 
by Cox (Cox, 1973)* To each 2 ml sample were added 0.5 ml of 26.2 mM 
borax and 0.2 ml 0.16 M FDNB. After heating at 60° for 30 min. in a 
shaking water bath, 0.2 ml 4M NaOH was added and heating continued for 
a further 15 min. The reaction was stopped by placing the tubes in ice. 
Cyclohexane (10 ml) was added and extraction carried out on a rotary 
mixer for 30 min. The cyclohexane layer was pipetted into pear-shaped 
flasks and evaporated to dryness in a rotary evaporator at 50°C. The 
residue was dissolved in 100 fil methanol; 10 jil of the reconstituted 
solution was injected onto an S5 0DS column with a mobile phase 
(Methanol : water, 93:7v/v) flow rate of 1 ml/min,
SPECTR0PH0T0METRIC MEASUREMENT OF N-DINITR0PHENYL PERHEXILINE:
A series of test tubes (duplicates) containing 0 - 1 0  jig/ml 
perhexiline were taken through the derivatization process previously 
described. The ultra-violet absorbance of the N-dinitrophenyl (DNP) 
perhexiline extracted into the cyclohexane layer was measured at 360 nm 
using a Cecil 272 linear read-out , Spectrophotometer (Cecil 
Instruments, U.K.).
SEARCH FOR A SUITABLE INTERNAL STANDARD:
Two compounds, hexadiline (2-[2,'2-dicyclohexyl ethylene] piperidine 
hydrochloride) and 2-(2'-cyclohexenyl, 2 '-cyclohexyl ethyl) piperidine 
hydrochloride, possessing structural and solubility similarities to 
perhexiline and its metabolites (Fig. 2.1) were considered as internal 
standard for the chromatographic analysis. Five test tubes containing
2.5 Ug/ml of these two compounds with and without 2.5 US< °T perhexiline 
were derivatised and analysed as ' befjore. . . . .
ou
DERIVATIZATION AND CHROMATOGRAPHIC ANALYSIS OF PERHEXILINE METABOLITES:
A series of test tubes containing 0 - 10pg of cis- and trans- 
monohydroxy-perhexilines were taken through the derivatization and 
chromatographic procedure described previously, (Methanol : water 
90 : 10 v/v), A sample containing only trans-monohydroxy-perhexiline 
was similarly analysed,
OPTIMIZING THE CONCENTRATION OF BORAX FOR DERIVATIZATION:
To four duplicate sets of test tubes containing 5 pg perhexiline,
5 pg cis-monohydroxy-perhexiline, 5*0 pg internal standard and 20 pg 
trans-monohydroxy—perhexiline were added 0,25 ml, 0,5 ml, 1,0 ml and
1.5 ml of 26,2 mM borax solution. After addition of 0,5 ml of 0,l6 M 
FDNB the tubes were derivatized and analysed as before, (mobile phase, 
Methanol : water, 90 : 10 v/v),
OPTIMIZING THE CONCENTRATION OF FDNB
To four duplicate sets of test tubes, as in the preceeding section, were 
added 0,1 to 1,0 ml of FDNB (0,16m ) and 1,5 ml of 26,2 mM borax. The 
samples were then derivatized and analysed as before (Mobile phase,
Methanol : water, 90 : 10 v/v),
OPTIMIZING THE TEMPERATURE AND TIME OF DERIVATIZATION
Three sets of duplicate test tubes containing 10 pg perhexiline,
2.5 pg internal standard, 10 pg cis-monohydroxy-perhexiline, 40 pg 
trans-monohydroxy-perhexiline, 1,5 ml 26,2 mM borax and 0,5 ml 
0,16 M FDNB were incubated at 60°C for 15 min, 30 min and 45 min.
The samples were analysed by h.p.l.c, as previously. (Mobile phase, 
Methanol : water, 90 : 10 v/v).
OPTIMIZING THE RESOLUTION OF SAMPLE COMPONENTS BY GRADIENT ELUTION:
From initial studies, Constametric I pump A was fed with methanol— 
water (85 s 15 v/v) and pump B with methanol. Using a flow rate of 
1 ml/min, the mobile phase composition, the gradient exponent and 
gradient time (Service manual, Gradient Master, Model 1601, L.D.C,, 
U.S.A.) were adjusted till adequate separation of the N-DNP derivatives 
of perhexiline, its metabolites and internal standard :was achieved with 
the minimum base-line drift. The time required for the mobile phase 
to equilibrate with the column on return to initial conditions was 
also noted,
RECOVERY STUDIES:
For recovery studies perhexiline or its metabolites were added to 
5 ml normal human blood plasma to give 0.5 - 10 pg drug or metabolite 
per ml of blood plasma. Duplicate (l ml) samples of the treated plasma 
were placed into 25 ml test tubes and 0.1 ml of 4 M NaOH added. After 
addition of 20 ml of diethyl ether, extraction was performed on a 
rotary mixer for 50 min and the organic phase removed; the extraction 
was repeated and the combined organic extracts evaporated to dryness 
at 40°C with the aid of a few anti bumping granules. The dried residue 
of the ether extract was heated at 80°C for 15 min with 1.5 ml of 26.2 mM 
borax and 0.5 ml of 0.16 M FDNB. Heating was continued for a further 
1 min after addition of 0.2 ml of 4M NaOH. The reaction mixture was 
cooled and the N-DNP derivatives extracted with 20 ml cyclohexane on a 
rotary mixer for 30 min. The cyclohexane layer was removed, evaporated 
to dryness under vacuum at 20°C and the residue redissolved in 100 pi
of methanol : water (85 : 15 v/v) for injection into the chromato­
graphic system. Reference duplicate test tubes containing 0,5 - 10 pg 
of drug and metabolites were similarly; derivatized. Samples were 
analysed chromatographically using gradient elution.
LINEAR RANGE AND LIMIT OF DETECTION:
Perhexiline, cis-monohydroxy-perhexiline and trans-monohydroxy- 
perhexiline (0 - 10 pg) were added to normal human blood plasma (l ml).
After addition of 250 ng of internal standard the samples were 
derivatized and analysed as described previously.
ACCURACY STUDIES:
In accuracy studies 0.1 - 10 pg of perhexiline and its metabolites 
were added to blank plasma (l ml) and coded by another individual* The
code was kept secret until the analysis of samples were completed.
PRECISION STUDIES:
For precision studies blank human blood plasma to which drug and 
metabolites (100 ng/ml perhexiline, 100 ng/ml cis-mono hydroxy-- 
perhexiline and 400 ng/ml trans-monohydroxy-perhexiline) had been 
added was divided into portions and stored at -20°C until analysed. 
Analysis of samples were performed over a 28 day period.
INTERFERENCE BY NITROGLYCERIN AND PROPRANOLOL:
Plasma to which perhexiline and metabolites, nitroglycerin and 
propranolol had been added were analysed as before.
ANALYSIS OF URINE SAMPLES:
Normal human urine to which drug and metabolites (0 - 10 pg/ml) 
had been added, were analysed as before.
RESULTS
DERIVATIZATION OF PERHEXILINE
The ultra-violet absorbance of the material extracted into the 
cyclohexane layer after derivatization was concentration dependent, 
indicating the formation of N-DNP derivative of perhexiline; a 
graph of the ultra violet absorbance of the extracted DNP derivative of 
perhexiline against the concentration of perhexiline in the sample 
produced a straight line (Fig. 2.2.).
Chromatograms of blank and test samples are shown in Figure 2.3A 
and B respectively. The retention time of N-dinitrophenyl perhexiline 
was 11.25 min. There was an impurity (x) in the perhexiline test 
samples eluting at 9 min (Fig. 2.3B): recrystallization of perhexiline
in ethyl acetate reduced this contaminant to negligible amounts. The 
peak height of DNP-perhexiline was proportional to the concentration 
of perhexiline in the test sample (Fig. 2.4.).
INTERNAL STANDARD
The retention times of the internal standard, perhexiline and 
hexadiline using a mobile phase of methanol : water, 93 J 7 v/v were 
10.75, 11.25 and 11.25 respectively (Fig. 2.5A and B). At this mobile 
phase composition no resolution occurred between perhexiline and 
hexadiline (Fig. 2.5B); slight, though significant, resolution was 
however achieved between perhexiline and the internal standard (Fig. 2.! 
Modification of the mobile phase composition (methanol : water, 90 : 10
resulted in adequate resolution of perhexiline and the internal 
standard (Fig. 2.5C).
DERIVATIZATION OF METABOLITES
Figure 2.6a  represents the chromatogram of a test sample containing 
a 4 : 1 mixture of trans- and cis-monohydroxy-perhexilines. The 
chromatographic peaks corresponding to the cis- and trans-metabolites 
of perhexiline were identified with the aid of a chromatogram of a test 
sample containing only the trans-metabolite. The retention times of 
the DNP derivatives of the trans- and cis-monohydroxy—perhexilines 
using a mobile phase of methanol : water, 90 : 10 v/v were 5 min 
and 5*25 min respectively. Further resolution of the DNP derivatives 
of the metabolites was attained with a mobile phase composition of 
methanol : water, 85 : 15 v/v (Fig. 2.6b ). The graphs of the peak 
height of DNP derivative of metabolite against the concentration of 
metabolite in the test sample produced straight lines (Fig. 2.7A and B).
OPTIMIZING THE DERIVATIZATION PROCEDURE
The effect of increasing the concentration of borax on the formation 
of DNP derivatives of perhexiline, internal standard, cis-monohydroxy- 
perhexiline and trans-monohydroxy-perhexiline is shown in Fig. 2.8.
Fig. 2.9 shows the effect of varying the concentration of FDNB on the 
formation of the DNP derivatives of the compounds of interest. There 
was approximately a 2 - 3 fold increase in the yield of DNP derivatives 
by increasing the temperature of derivatization from 60 to 80°C. By 
15 min (incubation) nearly maximum amounts of the DNP derivatives had 
been formed (Figs. 2.10.A and B).
CHROMATOGRAPHIC CONDITIONS.
Chromatograms of blank human blood plasma and plasma containing 
cis- and trans-monohydroxy-perhexiline, perhexiline and internal 
standard are shown in Fig* 2*11A and B. Elution was performed at 
20°C -with a flow rate of 1 ml/min. The gradient time and gradient 
exponent (Service manual, Gradient Master, Model 1601, L.D.C.,
U.S.A.) were 20 min and 3 min respectively. The initial mobile , 
phase composition was 95$ A and 5$ B with a final composition of 
40$ A and 60$ B. The final mobile phase composition was maintained . 
for a further 5 min before the run was terminated. The mobile phase 
was restored to its initial composition and allowed ten minutes to 
equilibrate with the column before another sample was injected into 
the chromatographic system.
VALIDATION OF H.P.L.C. METHOD:
The percentage recovery following ether extraction of perhexiline 
and its metabolites from blood plasma are shown in Table 2.1. The 
recovery ranged from 87 - 118$ with a coefficient of variation of 
10.5$ (n = 9)* The results of the accuracy study are shown in Table 2.2. 
The limits of detection of plasma perhexiline and metabolites 
corresponding to three times the recorder base-line noise were 15 ng/ml 
and 3 ng/ml respectively (Table 2.3)* The calibration curve of plasma 
perhexiline was linear over the range 15 ng/ml to 10 (Jg/ml and over the 
range 5 ng/ml to 10 (jg/ml for plasma cis— and trans-monohydroxy—perhexiline 
(Fig. 2.12.A, B. and C). There was a linear relationship between the 
peak height of the DNP derivative formed and the urinary concentration 
of drug and its metabolites (Fig3.,13)*
The coefficient of variation of replicate assays performed over a 
28 day period for 100 ng/ml plasma perhexiline, 100 ng/ml cis-
monohydroxy-perhexiline and 400 ng trans-monohydroxy-perhexiline were 
10*5$, 7*6$ and 5.6$ respectively (n = 9) (Table 2,4).
Nitroglycerin and propranolol did not interfere with the analysis 
of perhexiline and its metabolites,
DISCUSSION
The analysis of perhexiline and its metabolites in biological 
fluids has posed considerable difficulties in the past. Earlier 
pharmacokinetic studies of perhexiline in both animals (Leeson, et al,, 
1969a) and humans (Wright, 1970) were performed with ^C-perhexiline, 
These earlier studies did not however distinguish between unchanged 
perhexiline and its hydroxylated metabolites. Subsequently, a gas 
liquid chromatographic method was developed at the Merrell Research 
Centre (Cincinnati, Ohio, U,S.A.) for drug and metabolite measurement. 
Following an ether extraction of perhexiline-related materials from 
alkalinized urine, the residue of the ether (after evaporation) was 
derivatized with trifluoroacetic anhydride. The trifluoroacetyl 
derivatives of perhexiline and its hydroxylated metabolites were then 
measured by g,l,c, at 200°C on Vjo Versamide 900 column using 9-benzyli- 
denefluorene as the internal standard. The low sensitivity of this 
g,l,c, method limited its application to the analysis of urine samples 
(Wright, et al,, 1973).
In 1978, Lang and Co-workers described an improved g,l«c, method 
for the determination of perhexiline and its metabolites (Lang, et al,, 
1978), The procedure involved a double extraction step: an initial
extraction of alkalinized blood plasma with cyclohexane was followed 
by extraction of the cyclohexane with a hydrochloric acid solution.
An aliquot of the cyclohexane layer was evaporated to dryness and■ 
derivatized with trifluoroacetic anhydride. The trifluoroacetyl 
derivatives of drug and its metabolites were separated on a 5$
SE—30 on Chromosorb W—PH 80/100 mesh at 230°C connected to a 
flame ionization detector. This g,l.c, method permitted the 
simultaneous measurement of perhexiline and its hydroxylated 
metabolites in plasma. With a limit of detection of 0,25 (Jg/ml and 
a# linear range of 0,5 to 5 pg/ml of plasma perhexiline the method 
is only suitable for steady state kinetic analysis. Singlas and 
associates employed a modification of this procedure in investigating 
the steady state kinetics of perhexiline and metabolites in angina 
patients with and without neuropathy (Singlas, jit al#, 1978),
A more rapid and slightly more sensitive g,l.c, procedure for 
perhexiline determination in serum has recently been reported 
(Cooper and Turnell, 1980), Internal standard (Lignocaine) and 1 ml 
,1 M Tris buffer (pH 7*5) is added to 2 ml serum and extracted with 
15ml diethyl ether for a minute on a vortex mixer. After evaporation 
of diethyl ether the dried residue is dissolved in 20 (il diethyl 
• ether for injection (5 (jlI) onto a 10$ Carbowax 20 M - 2$ K0H on 
80/100 Chromosorb W AV at 205°C with flame ionization detection.
These workers achieved excellent extraction recoveries of nearly 
100$. (Coefficient of variation 4.1$). The limit of detection was 
0.09 (Jg/ml with a linear range of 0,4 - 4 (Jg/ml serum perhexiline.
The coefficient of variation of frozen sera assayed on different days 
for 0,5 (Jg/ml and 4 (Jg/ml serum perhexiline were 15. and 3*9$ (n ■« 15). 
The advantage of the Cooper and Turnell (1980) procedure over the 
earlier g,l,c, methods is its rapidity, a great asset in clinical 
therapeutic drug monitoring. The procedure has been used successfully
since its development for monitoring the serum levels of patients
on pexid with dose adjustment to reduce the incidence of perhexiline induced
neurotoxicity and hepatotoxicity (Cooper and Turnell, 1982). However
the low sensitivity of the procedure and the inability of the
procedure to measure the metabolites of perhexiline in serum or urine
makes it unsuitable for single dose kinetic studies.
Whilst the preseiit project was underway, Horowitz and associates 
(1981) in Australia, reported the development of a highly sensitive 
h.p.l.c. method for the measurement of perhexiline in human plasma.
Human blood plasma (l ml) is extracted with 7 ml of hexane following 
addition of 0,5 ml 2M Tris buffer (pH 8.75) and hexadiline (internal 
standard) on a vortex mixer for one minute. The hexane layer is 
evaporated to dryness under nitrogen at 6o°C. To the residue is added 
100 }il 0.1 M NaHCO^ and 100 (il 0.01 M dansyl chloride and the 
mixture heated at 37°C for 20 min. Hexane (3 ml) is added and 
extracted on a vortex mixer for 20 sec. The hexane layer is 
evaporated to dryness under nitrogen at 6o°C and the residue 
reconstituted in 100 (il of mobile phase (92.5 : 7.5 v/v, methanol : 
trater) 50 (il of the reconstituted solution is injected onto a 
Bondapack C^g reverse phase column (Waters Associates, U.S.A.), 
with a mobile phase flow of 1.2 ml/min. The fluorescence of the 
dansyl derivative of perhexiline is measured at standard excitation 
and emission wavelengths of 360 nm and 510 nm respectively. The 
limit of detection of this h.p.l.c. method is 5 ng/ml plasma perhexiline 
with a linear range of 5 ng - 5 (Jg/ml. These workers achieved an 
extraction recovery of 40$. The coefficient of variation of replicate 
recoveries of perhexiline from pooled plasma (150 ng/ml perhexiline)
was 8.5$ (n = 8). The sensitivity of the method is about a 100 
times that of the earlier g.l.c. methods and about 20 times that 
of the Cooper and Turnell (1980) method. The method has been 
employed successfully in a single dose kinetic study in five 
elderly patients with angina pectoris. This analytical method 
does not, however, permit the determination of perhexiline 
metabolites in plasma; the suitability of this method for urine 
samples has also not been investigated. Defective metabolism of 
perhexiline probably genetic or otherwise has been implicated in 
perhexiline—induced peripheral neuropathy (Singlas. et al.. 1978;
Shah, .et ail,, 1982). Thus the importance of measuring the major 
hydroxylated metabolites of perhexiline in both plasma and urine in 
kinetic studies cannot be over emphasised.
The ultra violet spectrophotometric h.p.l.c. procedure developed 
in this chapter is essentially quantitative with an accuracy of 
between 90 - 110$ (Table 2.2). The limits of detection of plasma 
perhexiline and monohydroxy perhexiline were 15 ng/ml and 3 ng/ml 
respectively. The method is about three times less sensitive than the 
fluorescent h.p.l.c. method of Horowitz and associates (1981); it is, 
however, about 6 - 1 5  times more sensitive than the g.l.c. methods.
Its precision is comparable to those of the Cooper and Turnell (1980) 
g.l.c. and the Horowitz et al., (1981) h.p.l.c. methods. The rather 
time consuming and tedious extraction procedure and the long chromato­
graphic analysis time (35 - 45 min per sample) however, precludes its 
use in routine therapeutic plasma drug monitoring of angina patients 
on perhexiline therapy. This analytical procedure permits the 
simultaneous analysis of perhexiline and its major metabolites in 
biological fluids; the relatively high sensitivity of this procedure
therefore makes it the most suitable analytical method for single dose 
perhexiline kinetic studies to date.
TABLE 2.1
RECOVERIES OF PERHEXILINE AND ITS MONOHYDROXY 
METABOLITES FROM HUMAN BLOOD PLASMA.
Plasma
Concentration
(pg/ml)
Recovery" of 
cis-metabolite
o o
Recovery of 
Trans-metabolite 
($)
Recovery of 
Perhexiline
($)
0.5 87 93.5 102
2.0 - 87 108
2.5 101 - -
10.0 100 118 112
Coefficient of variation of recovery 10.5$ (n = 9)
c*
TABLE 2.2.
ACCURACY OF RECOVERIES OF PERHEXILINE AND ITS 
MONOHYDROXY METABOLITES FROM HUMAN BLOOD PLASMA
Amount of drug/ 
metabolite added 
to plasma (l ml)
(us)
CIS-MONOHYDROXY
PERHEXILINE
0.10
0.40
1.00
2.50
4.00
8.00
TRANS-MONOHYDROXY
PERHEXILINE
PERHEXILINE
0.40
1.60
10.00
0.10
0.40
1.00
2.50
4.00
10.00
Amount of drug/ 
metabolite found 
on analysis by 
H.P.L.C. (jjg)
0.09
0.42
1.10
2.56
4.40
7*80
100 x Amount found 
Amount added
0.39
1.76
9.43
0.095
0.41
1.04
2.52
4.36
10.00
90
105
110
102
110
97
97
110
94
95 
102 
104 
100 
109 
100
TABLE 2.3.
SENSITIVITY OF THE H.P.L.C. DETERMINATION OF 
PERHEXILINE AND ITS MONOHYDROXY METABOLITES 
ADDED TO HUMAN BLOOD PLASMA
Drug/metabolite Limit of detection 
ng/ml plasma
Trans-monohydroxy
—perhexiline 3.0
Cis-monohydroxy
-perhexiline 3.0
Perhexiline 15.0
TABLE 2.4.
PRECISION OF H.P.L.C. METHOD FOR DETERMINATION 
OF PERHEXILINE AND ITS MONOHYDROXY METABOLITES
Plasma
Concentration
ng/ml
Drug/metabolite Coefficient of 
Variation ($)
n = 9
100 Perhexiline 10.5
100 Cis-metabolite 7.6
400 Trans-metabolite 5.6
Figure 2.1 The structure of perhexiline 
and related compounds
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Figure 2.2. Derivatization of Perhexiline
Variation of ultraviolet absorbance of cyclohexane layer with 
the concentration of perhexiline.
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Variation of peak height of dinitrophenyl derivative of 
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A: Chromatogram of test sample containing trans (M^)- and
cis (M^)-monohydroxy-perhexilines.
B: Resolution of and using mobile phase of 85:15 v/v,
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Figure 2,7.A, Beer1s law plot
Variation of peak height of DNP derivative formed with 
concentration of trans-monohydroxy-perhexiline.
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Figure 2.7.B. Beer1s lav plot
Variation of peak height of DNP derivative with 
concentration of cis-monohydroxy-perhexiline.
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Figure 2.8. Optimizing Derivatization Conditions
Effect of increasing the amount of Borax (26,2 mM) on the 
formation dinitropheny derivatives of perhexiline ( ■ ), 
internal standard ( □ ), cis ( • )- and trans ( O  )- 
monohydroxy perhexilines.
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Figure 2.9* Optimizing derivatization conditions
Effect of increasing the amount of 0.16m FDNB on the 
formation of dinitrophenyl derivatives. Key to symbols 
as in Figure 2.8.
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Figure 2*10,A, Optimizing incubation conditions
Effect of incubation time on the formation of DNP 
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Figure 2.10.B. Optimizing incubation conditions
Effect of incubation time on the formation of DNP 
derivatives at 80°C. Key to symbols as in Figure 2.8
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1. Typical Chromatograms
Chromatograms of blank human blood plasma (A) and human blood
plasma wit^/idded perhexiline, P (500 ng/ml), cis-metabolite
(100 ng/ml), trans-metabolite (400 ng/ml) and internal
standard, S (250 ng/ml). H.P.L.C. conditions:
Pump A Methanol : Water (85 : 15 v/v)
Pump B Methanol
Initial conditions, 95$ A and 5$ B
Final conditions, 40$ A and 60$ B
Gradient time, 20 minutes; Mobile phase flow rate,l ml/min.
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Variation of peak height ratio of perhexiline/internal 
standard with the plasma concentration of perhexiline.
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Variation of peak height ratio of trans-monohydroxy-perhexili 
internal standard with plasma trans-monohydroxy perhexiline 
concentration.
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Variation of peak height ratio of cis-monohydroxy-perhexiline 
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Figure 2.13* Beer1s lav plot
Variation of peak height with urine concentration of 
perhexiline ( O ), cis ( A )- and trans ( □ )-monohydroxy- 
perhexiline,
CHAPTER .3
A LIMITED SINGLE DOSE PERHEXILINE 
PHARMACOKINETIC STUDY IN HOMAN VOLUNTEERS
INTRODUCTION
In Chapter 2 a sensitive ultra-violet spectrophotometric h.p.l.c. 
method was developed for the analysis of perhexiline and its major 
metabolites, cis-monokydroxy-perhexiline (M^) and trans-monohydroxy— 
perhexiline (M^).
To ascertain the adequacy of this analytical method for single 
dose kinetic studies in humans a limited study was undertaken with five 
human volunteers.
EXPERIMENTAL
CLINICAL STUDY
The approval of the ethical committees of the University of Surrey 
and St. Luke's Hospital, Guildford, was obtained for the study. On the 
basis of a normal physical examination and routine investigations and 
screening for renal and hepatic function, five healthy adult male 
consenting volunteers aged 23 - 46 years, were accepted for the study.
After an overnight fast, each volunteer received 150 mg Pexid orally: 
fasting was continued for a further three hours before the subjects were 
allowed a light lunch. Blood samples (7 ml) were withdrawn into 
heparinised tubes over an eight-hour period from an intravenous 
catheter inserted into a forearm vein. A two-hourly urine collection 
was made for the first eight hours after drug administration, with a 
final pooled collection from 8 - 2 4  hours after drug administration.
Plasma and urine samples were stored at -20°C until required for analysis.
A week later (when perhexiline and metabolites were undetect­
able in the plasma and urine) the study was repeated with 300 mg Pexid; 
an additional blood sample was taken 24 hours after drug administration.
SAMPLE PREPARATION AND ANALYSIS BY H.P.L.C.
Plasma or urine samples (l.O ml) containing 250 ng internal 
standard were taken through the extraction and derivatization procedures 
previously described in Chapter 2 and subsequently analysed by h.p.l.c. 
using gradient elution.
RESULTS
The ages and body weights of subjects taking part in the study and 
the dose of perhexiline (mg/Kg body weight) received by the subjects 
are shown in Table 3*1* The results of pre-dosing laboratory investi­
gations carried out on participants are shown in Table 3*2. The time 
courses of plasma perhexiline and monohydroxy-perhexiline concentrations 
following the oral administration of Pexid in the five volunteers are 
shown in Figure 3*15 Figure 3.2 shows the cumulative urinary excretion 
of perhexiline and cis- and trans-monohydroxy—perhexilines after oral 
Pexid in the five subjects.
At the 150 mg (low-dose) study perhexiline was undetectable in 
plasma over the eight hour sampling period in subject J.D.; this, 
subject, however, had the highest cis-monohydroxy-perhexiline levels 
( 0.5 pg/ml) compared with the other volunteers (Fig. 3.1)* Three
subjects, J.B., A.D. and S.G. had significant plasma unchanged perhex­
iline. Trans-monohydroxy-perhexiline was either undetectable (j.D.) 
or very low in the plasma of J.B., A.D. and S.G. (Fig. 3*1)* The
highest plasma unchanged perhexiline levels were observed in the fifth 
volunteer E.E.; at eight hours post-dose,the plasma concentration of 
perhexiline was still rising: both cis- and trans-monohydroxy-perhexiline
were undetectable in his plasma. By two hours following drug 
administration both cis- and trans-monohydroxy-perhexilines were present 
in the urine, albeit in trace amounts in J.D., J.B., A.D, and S.G.
(Fig. 3.2): at 24 hours post-dosage, cis-monohydroxy-perhexiline was
present in the urine in higher amounts than the trans isomer, and there 
was no unchanged perhexiline in the urine in these subjects. In the 
fifth subject E.E., cis-monohydroxy-perhexiline was undetectable in 
the urine: the trans-metabolite was present in relatively small amounts
in comparison with the other subjects. Subject E.E. did excrete 
significant amounts of unchanged perhexiline in his urine (Fig. 3*2).
At the 300 mg Pexid dose study (high-dose) low levels of plasma 
unchanged perhexiline were observed in subject J.D., with again very 
high plasma cis-monohydroxy-perhexiline levels ( 1 jjg/ml). The
levels of both the cis- and trans-metabolites of perhexiline in the 
plasma were higher in the high-dose than the low-dose study (Fig. 3*1)*
In J.B., A.D. and S.G. plasma perhexiline and metabolite levels were 
higher at the high-dose than the low-dose study. At 8 hours post— 
dose, plasma perhexiline and metabolites levels were still rising in 
J.B. Monohydroxy-perhexilines were undetectable in the plasma of 
TUE.J this subject again had the highest plasma unchanged perhexiline 
levels. At 24 hours post-dose, cis-monohydroxy-perhexiline was present 
in higher amounts in the urine than trans-monohydroxy-perhexiline in 
subjects J.D., J.B. and A.D. One subject S.G. had a reversed pattern 
at the high-dose study with the trans-metabolite in higher amounts than 
the cis-metabolite at the end of 24 hours following drug ingestion (Fig. 3
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TABLE 3*1#
Human volunteers participating in the 
single dose perhexiline studies
Volunteer Age
(years)
Weight
(Kg).
Low Dose Study 
(mg perhexiline/ 
Kg body weight)
High Dose Study 
(mg perhexiline/ 
Kg body weight)
J.D. 32 70 2.1 4.2
J.B. 33 83 1.8 3.6
A.D. 31 55 2.7 5.4
S.G. 23 68 2.2 4.4
E.E. 46 83 1.8 3.6
Mean 33 71.8 2.1 4.2
None of the volunteers was taking other drugs during the study. 
All volunteers were males.
Time 
after 
dosing 
(hi
Figure 3«i« Perhexiline pharmacokinetics
Plasma perhexiline (• o) and cis- (± £* ) and trans- (• a ) 
metabolite time course after oral administration of 150 mg 
(closed symbols) and 300 mg (open symbols) Pexid tablets to 
human volunteers.
plasma perhexiline and metabolites (pg/ml)
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Figure 3«2, Perhexiline pharmacokinetics
Cumulative urinary excretion of perhexiline and metabolites 
after oral administration of 150 mg and 300 mg Pexid tablets 
to human volunteers. Key to symbols as in Figure 3.1*
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DISCUSSION
Despite the proven efficacy of perhexiline maleate in the prophy­
lactic treatment of angina pectoris and its reported superiority over 
some (3-adrenergic blocking drugs in the treatment of angina pectoris 
(Armstrong, 1973? Affcal—Mir and Kaf'ehzaki.sf, 1978> Pilcher,, 1978) the 
prescription of perhexiline remains limited on account of the frequency 
and severity of some adverse reactions to the drug. The mechanism of 
perhexiline-induced neuropathy and hepatotoxicity is still not clear, 
although a disorder in perhexiline metabolism has been suggested as 
a possible factor (LfHermitte, et al«, 1976), In 1978, Singlas and 
associates (Singlas, et aJU* 1978) investigated the steady state 
pharmacokinetics of perhexiline in a group of 13 patients with 
perhexiline-induced peripheral neuropathy and 14 patients on perhexiline 
but without neuropathy. The mean plasma perhexiline levels of the 
patients without neuropathy was about 1 pg/ml: the group with
neuropathy had a significantly higher mean plasma perhexiline levels of 
3*8 (jg/ml. The neuropathic patients also had slower hepatic 
metabolism of perhexiline and longer plasma perhexiline half-life.
Though the present single-dose study was limited in the numbers of 
volunteers studied and the duration of blood and urine sampling, a few 
interesting points did emerge from the study. Considerable individual 
variation with respect to the metabolism and clearance of perhexiline 
was observed (Figs. 3*1 and 3.2), This supports the earlier human 
kinetics study using *\j-perhexiline (Wright, jet ,al*, 1973)* In four 
subjects (J.D., J.B., A.D, and S.G.) perhexiline exhibited marked first 
pass metabolism with plasma metabolite levels higher than unchanged 
perhexiline. This might explain the observed initial delay between
perhexiline administration and the onset of drug effect (Luccioni and 
Trigano, 1973)* The major metabolite of perhexiline in both plasma and 
urine of three subjects, J.D., J.B, and A.D. was cis-monohydroxy-- 
perhexiline. In a fourth subject, S.G., the cis-metabolite was also 
the major metabolite in the plasma, and in the urine at the low-dose 
study; at the high-dose study, however, the trans isomer became the 
major metabolite in the urine at 24 hours. The metabolism of 
perhexiline could thus be subject to saturable kinetics with respect 
to cis-hydroxylation. The amount of trans-monohydroxy-perhexiline in 
the urine of all five volunteers was greater than might have been 
expected from the plasma concentrations of this metabolite. This 
could be due to further metabolism of the cis-metabolite or to 
preferential excretion of the trans isomer.
The fifth subject, E.E., appeared to have a defective capacity to 
liydroxylate perhexiline. The cis- and trans-monohydroxy-metabolites of 
perhexiline were not detectable in the blood plasma and the concentration 
of unchanged perhexiline in the plasma was much higher than in the other 
four subjects. Much lower amounts of perhexiline metabolites were 
excreted in the urine in this subject; significant excretion of 
unchanged perhexiline also occurred. The major metabolite in this 
subject was the trans-monohydroxy-isomer. It is interesting to note 
that the neuropathic patients of Singlas and associates (Singlas, et al.t 
1978) also excreted more trans-monohydroxy perhexilines than their 
non-neuropathic counterparts. In the absence of clinical or laboratory 
evidence of liver dysfunction, the observed impairment in drug oxidation 
is probably genetic in origin (Shah, et jal., 1982). An individual such 
as E.E. if given the conventional dosage of perhexiline over prolonged
periods is likely to accumulate the drug with consequent drug-induced 
toxicity.
This limited kinetic study proved that the ultra violet spectro- 
photometric h.p.l.c. method is of adequate sensitivity for single dose 
kinetic studies in humans. The above preliminary kinetic study suggests 
that single dose perhexiline kinetics may be of value in identifying 
those at risk of toxic accumulation of perhexiline on conventional 
dosage regimes. Further studies are however needed to elucidate the 
complexities of perhexiline metabolism and kinetics and to fully 
evaluate the use of single dose kinetics in predicting potential 
adverse reactions to perhexiline.
CHAPTER 4
AN EXTENDED SINGLE-DOSE PERHEXILINE 
PHARMACOKINETIC STUDY IN HUMAN VOLUNTEERS
INTRODUCTION
In Chapter three, the h.p.l.c. method described previously was 
employed successfully in a single-dose pharmacokinetic study of perhexiline. 
This study was, however, limited in the number of volunteers studied 
and more importantly in the duration of blood and urine sampling. An 
extended single-dose study was therefore carried out in 8 normal healthy 
volunteers.
EXPERIMENTAL
CLINICAL STUDY
Eight consenting healthy adults (4 females and 4 males), were 
screened for liver and renal disease as described before (Chapter 3)*
After an overnight fast, each volunteer emptied the bladder prior to 
ingestion of 300 mg Pexid tablets. Blood samples (7 ml) were withdrawn 
from an intravenous catheter inserted into a forearm vein at 2, 4, 6, 8,
10, 12, 16, 20, 24 hours after drug administration; additional blood 
samples were withdrawn by venepuncture at 30 and 48 hours post-dosage.
Urine was collected daily for 5 days after drug administration. The 
blood plasma and urine samples were stored and analysed by h.p.l.c. as 
described previously.
PHARMACOKINETIC ANALYSIS
Preliminary estimate of rate constants were obtained by fitting 
plasma concentration-time data to the bi-exponential equation (eq. 18) 
of the open one compartment extra vascular model, using
simple linear regression analysis of the residuals. Pharmacokinetic 
parameters were subsequently obtained using a non linear least square 
regression computer programme (Metzler, et£i«» 1974), The area'under the
plasma time curve AUC was estimated, using the trapezoidal method from 
time zero to 48 hours(cis- and trans-monohydroxy-perhexiline) or from 
time zero to 48 hours and extrapolating to infinity (perhexiline)
(Ritschel, 1980).
RESULTS
The characteristics of subjects participating in the study are 
shown in Table 4.1. The mean age and body weight were 27.6 i 1.4 years 
and 58.9 - 4.7 Kg respectively; the dose of perhexiline received ranged 
from 3*6 - 7.0 mg per Kg body weight (mean 5.3 — 0.4 mg per Kg). The 
plasma perhexiline and metabolite-time profiles of the volunteers are 
shown in Fig. 4.1.A - 4.8.A. Plasma cis-monohydroxy-perhexiline levels 
were always higher than plasma unchanged perhexiline levels. Plasma 
trans-monohydroxy-perhexiline .was either undetectable (Figs. 4.2.A., 
4.3.A., 4.4.A., 4.8.A.) or very low (Figs. 4.I.A., 4.5.A., 4.6.A., 4.7.A.). 
At 48 hours, perhexiline was still present in the plasma albeit in low 
concentrations in all volunteers except H.L. (Fig. 4.3.A.), The cis- 
monohydroxy-perhexiline levels at 48 hours were relatively much higher 
than that of unchanged perhexiline.
The pharmacokinetic parameters from plasma-time curves are shown 
in Table 4.2. Peak plasma perhexiline and cis-monohydroxy-perhexiline 
levels occurred at 6.5 - 0.7 and 7.5 - 0.7 hour post-dosage; the 
corresponding peak drug and metabolite levels were 112 — 20 and 473 — 43 ng 
ml"'*'. The AUC of plasma perhexiline ranged between 813 - .6,077 ng. hour 
ml"'*' (mean 2,830 - 603 ng. hour ml"’"*'); the AUC of cis-monohydroxy- 
perhexiline was 11,098 i 408 ng. hour ml \  The plasma elimination 
half-lives of perhexiline and its cis-metabolite were 14.2 - 1.9 and 
26.8 i 4.4 hours respectively.
The cumulative urinary excretion of cis- and trans-monohydroxy- 
perhexilines are shown in Figs. 4.1.B, - 4.8.B. By the fifth day post­
dosage, t h e m e t a b o l i t e  excretion was approaching a pUWau in 
6 subjects (Figs. 4.I.B., 4.2.B., 4.3.3., 4.4.B., 4.6.B., and 4.8.B.); 
in two other subjects A.D. and S.G., however, the cu*r>u\ctWtcis- and 
trans-monohydroxy-perhexiline excretion was almost linear over the five- 
day period (Figs. 4.5.B. and 4.7.B.). Between 3 and 23 per cent of the 
oral dose of perhexiline was excreted as monohydroxy—perhexilines in 
5 days (mean 11.93 - 2«17^)> trace amounts of perhexiline were also 
excreted in the urine (Table 4.3.). The urinary ratio of trans- to 
cis-monohydroxy-perhexiline ranged from 0.32 to 0,89 (mean 0.52 - 0.7).
The daily urine output over the 5-day period after drug administration 
is depicted in Fig. 4.9. Generally, an initial diuresis (subjective) 
was followed by a fall in urine output on the second day in five 
subjects (R.O., Y.L., H.L., N.G., J.B. and S.P.); in a sixth subject 
S.G., who admitted to drinking several pints of beer from the second 
day post-dosage, the fall in urine output occurred on the third day.
In A.D. there was no marked alteration in the daily urine output 
following drug administration,
DISCUSSION
Following administration of a solution of ^4C-perhexiline maleate 
(100 mg) to 4 volunteers, drug absorption was nearly complete 6 — 12 hours 
later (Wright, et jal., 1973). In 5 elderly patients with ischaemic 
heart disease, peak plasma perhexiline concentrations occurred 3 - 1 8  hours 
(mean 7.0 i 2,8 hours) after an oral dose of 300 mg perhexiline maleate; 
considerable variation in the rates of drug absorption was observed 
(Horowitz, ejb aJL., 1981). In the present study peak plasma perhexiline 
concentration occurred at 6.5 — 0.7 hours after drug administration;
peak plasma level of cis-monoliydroxy-perhexiline occurred about
the same time as that of unchanged perhexiline. The extent of drug
absorption following administration could not be estimated for practical
14reasons. Of the orally administered dose of C-perhexiline maleate, 
between 52 and 95$ of the dose was absorbed (Wright, jet _al., 1973).
Marked presystemic metabolism of perhexiline was observed, 
confirming the finding reported previously in Chapter 2. Extensive 
presystemic drug elimination occurs with drugs that are relatively 
well extracted by the liver (Boyes, jet jal., 1971; Shand and Rangnp, 1972). 
A consequence of presystemic drug metabolism is a decrease in systemic 
drug availability and low plasma drug levels (Harris and Riegelman, 1969;
Gibaldi, jet al«, 1971). Furthermore, the 
systemic availability of highly extractable drugs after oral administration, 
is markedly influenced by differences in intrinsic hepatic drug clearance 
(Kornhauser, et jal., 1978; Alvan, qt ail., 1977). Thus the observed 
variation in the "apparent systemic availability" (AUC) of perhexiline 
may have been due to both variable drug absorption and differences in 
intrinsic hepatic drug clearance.
The major route of metabolism of perhexiline is hydroxylation of 
the cyclohexyl rings (Fig. 1.2.) (Wright, et al(, 1973). In the 
present study, cis-hydroxylation of perhexiline was the predominant 
metabolic pathway in all subjects, confirming the earlier studies of 
Wright, ejfc jal., (1973) and the limited study described previously in 
Chapter 3* Despite low plasma trans-monohydroxy-perhexiline levels, 
there was substantial urinary excretion of this metabolite; this 
metabolite constituted about 24 - 27$ of the total urinary metabolite 
excretion in the five days after drug administration. A probable 
explanation for the low plasma trans-metabolite levels is a relatively fast<
metabolite elimination than formation. The metabolism of perhexiline 
exhibits stereoselectivity with urinary trans-/cis-monohydroxy~
perhexiline ratios of 0.32 — 0.89 (Table 4.3). There is evidence in 
the rat to indicate that cyclohexyl hydroxylation involves more than 
one form of cytochrome P-450 (May, _et al,., 1975). It has also been 
observed that the presence of large substituents adjacent to the 
cyclohexyl ring controls the sites of hydroxylation of the cyclohexyl 
moiety by influencing the specificity of binding to cytochrome P-450 
(Fish, et al,, 1977).
The 5-day cumulative urinary excretion of monohydroxy-perhexilines
varied from 3 - 23$ of the orally administered dose of perhexiline;
unchanged perhexiline was undetectable or present in the urine in very
low amounts (Table 4.3). In a comparative period, between 5 - 33$ of
14the administered single-dose of C-labelled perhexiline maleate
(calculated from data presented in Wright, 1973) "was excreted
in the urine; no unchanged perhexiline was detected in the urine.
The administration of perhexiline was followed by prolonged excretion
of drug-related materials (obviously perhexiline metabolites) in the
14urine; 22 days after drug ingestion, C was still detectable in the 
urine of volunteers (Wright, _et al,, 1973). The plasma elimination 
half-life of perhexiline and its major cis-metabolite were 14.2 — 1.9 hours 
and 26.8 i 4.4 hours respectively, (Table; 4.2.). In view of the 
prolonged excretion and the large AUC of cis-monohydroxy-perhexiline 
(Table 4.2), and the reported pharmacological activity and toxicity of 
several drug metabolites) it will be interesting to know whether the 
metabolites of perhexiline possess any activity and/or toxicity.
Indirect evidence, however, indicates that perhexiline metabolites 
were not responsible for, at least, perhexiline-induced peripheral
neuropathy; the steady-state plasma concentration of cis-monohydroxy- 
perhexiline was lower (1.6 (jg/ml) in patients with neuropathy than in 
those without (3*8 fjg/ml); the concentration of the trans-metabolite 
in the two groups were essentially the same (Singlas, et al., 1978).
No statistically significant difference in pharmacokinetic 
parameters (except in AUC) were observed between healthy young female 
and male adults (Table 4.4). Also the pharmacokinetic parameters of 
the elderly ill male patients of Horowitz, _et a_l., 1981, were not 
significantly different from those of the healthy young males in the 
present study (Table 4.5). The number of subjects involved in these 
comparisons are however too small for any meaningful conclusions to 
be drawn. The marked reduction in urine output on the second to third 
day after drug administration may be detrimental to patients with 
impaired renal function. Controlled studies are, however, needed to 
assess the full significance of the post-diuretic fall in urine output 
following perhexiline administration.
Table 4.1,
CHARACTERISTICS OF SUBJECTS PARTICIPATING IN SINGLE DOSE 
PERHEXILINE PHARMACOKINETIC STUDY
Subject Sex Age
(yr)
Body Weight 
(Kg)
Dose of Pexid 
(mg/Kg)
R.O. Female 27 57 5.3
Y.L. Female 28 47 6.3
. \H.L. Female 23 50 6.0
N.Q. Female 23 43 7.0
A.D. Male 31 55 5.4
J .B g Male 34 83 3.6
S.G. Male 23 68 4.4
S.P. Male 30 68 4.4
Mean 27.6 58.9 5.3
S.E.M. 1.4 4.7 0.4
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Pig. 4.I.A.
Time courses of plasma perhexiline and metabolites following oral
administration of 300 mg Pexid tablets. Subject R.O.
Key to symbols 
• unchanged perhexiline 
▲ cis-monohydroxy-perhexiline 
■ trans-monohydroxy-perhexiline
0.4
0.3
0.2
0.1
168 24 32 48
Time after dosing (hour)
Pl
as
ma
 
pe
rh
ex
il
in
e 
an
d 
me
ta
bo
li
te
s 
(}
ug
/m
l)
Fig. 4.2.A.
Time courses of plasma perhexiline and metabolites following oral
administration of 300 mg Pexid tablets. Subject Y.L.
Key to symbols as in 4.1.A.
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Fig. 4.3.A.
Time courses of plasma perhexiline and metabolites following oral
administration of 300 mg Pexid tablets. Subject H.L.
Key to symbols as in Fig. 4.1.A.
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Fig. 4.4.A.
Time courses of plasma perhexiline and metabolites following
oral administration of 300 mg Pexid tablets. Subject N.G. 
Key to symbols as in Fig. 4.1.A.
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Fig. 4.5.A.
Time courses of plasma perhexiline and metabolites following
oral administration of 300 mg Pexid tablets. Subject A.D.
Key to symbols as in Fig. 4.1.A.
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Fig. 4.6.A.
Time courses of plasma perhexiline and metabolites following oral
administration of 300 mg Pexid tablets. Subject J.B.
Key to symbols as in Fig. 4.1.A.
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Fig. 4.7.A.
Time courses of plasma perhexiline and metabolites following
oral administration of 300 mg Pexid tablets. Subject S.G.
Key to symbols as in Fig. 4.1.A.
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Fig. 4.8.A,
Time Courses of plasma perhexiline and metabolites following oral
administration of 300 mg Pexid tablets. Subject S.P.:
Key to symbols as in Fig. 4.1.A.
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Fig. 4.I.B.
Cumulative urinary excretion of monohydroxy-perhexilines following
oral administration of 300 mg of Pexid tablets. Subject R.O. 
Key to symbols:
A cis-monohydroxy-perhexiline 
□ trans-monohydroxy-perhexiline
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Fig. 4.2.B.
Cumulative urinary excretion of monohydroxy-perhexilines following
oral administration of 300 mg Pexid tablets. Subject Y.L.
Key to symbols as in Fig. 4.1.B
12
10
8
6
5
4
3
2
1
4 51 2
Time after dosing (days)
Cu
mu
la
ti
ve
 
ur
in
ar
y 
ex
cr
et
io
n 
of 
mo
no
hy
dr
ox
y—
pe
rh
ex
il
in
es
 
(m
g)
Fig. 4.3.B.
Cumulative urinary excretion of monohydroxy-perlicxilines following
oral administration of 300 mg Pexid tablets. Subject II.L. 
Key to symbols as in Fig. 4.I.B.
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Fig. 4.4.B.
Cumulative urinary excretion of monohydroxy-perhexilines following
oral administration of 300 mg Pexid tablets. Subject N.G. 
Key to symbols as in Fig. 4.I.B.
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Fig. 4.5.B.
Cumulative urinary excretion of monohydroxy-perhexilines following
oral administration of 300 mg Pexid tablets. Subject A.D. 
Key to symbols as in Fig. 4,1.A.
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l?ig» 4.6.B.
Cumulative urinary excretion of monohydroxy-perhexilines following
oral administration of 300 mg Pexid tablets. Subject J.D. 
Key to symbols as in Fig. 4.I.B.
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Fig. 4.7.B.
Cumulative urinary excretion of monohydroxy-perhexilines following
oral administration of 300 mg Pexid tablets. Subject S.G. 
Key to symbols as in Fig. 4.I.B.
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Fig. 4.8.B.
Cumulative urinary excretion of monohydroxy-perhexilines following
oral administration of 300 mg Pexid tablets. Subject S.P.
Key to symbols as in Fig. 4.I.B.
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Urine output following oral administration of 300 mg Fexid
tablets in 8 volunteers. 
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Table 4.4.
Influence of gender on perhexiline pharmacokinetics following
+ingestion of 300 mg Pexid tablets. Values are means - S.D.;
S = significant, NS = not significant*
Test of significance is the unpaired student's t-test.
Parameter Females Males Significance
Number (n) 4 4 -
Age (yr) 25.8 -  2.2 29.5 -  k.i NS
Dose (mg Kg ") 6.2  -  0.7 4.5 -  0.7 S (p 4  0.02)
Peak plasma perhexiline time 6 .5  -  2.5 6 .5  -  1.9 NS
(hour)
Peak plasma perhexiline
concentration (ng ml 85 -  19 141 i  63 NS (p >  0 .2 )
Peak plasma cis-metabolite
time (hour) 00
 1 +
■
(■—1 • Os 7 -  2.3 NS
Peak plasma cis-metabolite
concentration (ng ml ) 470 i  180 480 -  50 NS
AUC - perhexiline
(ng. hour ml ^) 1,680 i  630 4,oooi 1,700 S (p ^  0 . 05)
AUC - cis-metabolite 1
(ng, hour ml ^) L2,300 -5,100 8, 000^ 5,000 NS (p >  0.030)
Plasma ti (perhexiline)(hour)
p
11.6 -  3.8 l6 .8 i  6.1 NS
Plasma ti (cis metabolite)
2
(hour) 32.7 -  15.4 20.8 i  5.7 NS
Urinary metabolite
(Trans/cis) ratio 0.41 -  0.08 0.64 -  0.23 NS
Metabolite excretion in 5 days
{jo of dose) 5.7 -  3.6 11.1 i  3.4 NS (p> 0.05)
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CHAPTER 5
STEREOSELECTIVE DISPOSITION AND PHARMACOKINETICS 
OF PERHEXILINE ENANTIOMERS
INTRODUCTION
The asymmetry inherent in biological systems results in 
diastereomeric interactions between small chiral molecules and the 
binding sites of biomacromolecules (Low, et a_l., 1978). These steric 
interactions may contribute to the stereochemical differences in 
pharmacological activity reported for a variety of asymmetric drugs 
(Daniels and Jorgensen, 1977? Rama Sastry, 1973? Patil, _et aJL., 1975? 
Casy, 1970; Hewick and McEwen, 1973; Vlasses, .et al,, 1981; Irwin et al. 
1980; Zacchei £t al,, 1980; Tobert, ejfc a^ .., 1980). Stereochemical 
differences in pharmacological activity may result from diastereomeric 
interactions with membrane components involved in transport (Gray, ut al. 
1976; Ames, et al,, 1977), with receptors (Jacquet et al.. 1977;
Mohler and Okada, 1977; Sullivan, ejfc jEL., 1975; Geber, et al,, 1977), 
and with enzymes responsible for the stereo-selective metabolism of drugs 
(jenner and Testa, 1973; Caldwell, 1976). Enantiomeric differences in 
drug disposition may be due to differences in drug absorption (de Oong, 
1977), distribution (Schmidt and Jahnchen, 1977; Kawashima, et al., 1976 
Levy, ejb aJL•, 1976; metabolism (Feller and Malspeis, 1977; Mttlndermans, 
et-ai*, 1976; George, et aJL., 1972; Ehrsson, 1975) and excretion 
(Breimer and vanRossum, 1973; Vangiessen and Kaiser, 1975; Werring'loer 
and Estabrook, 1975)•
Three types of stereoselective metabolism have been defined recently 
(Testa and Jenner, 1976; ), viz;
1. Substrate—stereoselectivity: in which the enantiomers of a 
chiral molecule are metabolized at different rates.
2. Product-stereoselectivity: in which a prochiral centre of a
molecule is metabolized at different rates to two or more stereo­
isomers and
3. Substrate-product stereoselectivity; in which a chiral molecule 
is metabolized at different rates to yield different amounts of the 
possible diastereomers.
An enantiomer of a racemic mixture may influence the metabolism of 
its optical antipode; such an enantiomeric interaction has been 
implicated in the in vitro metabolism of emphetamine (Gal, et al,, 1976); 
Wright, et al., 1977)® The (-)enantiomers of ibuprofen and cicloprofen 
are capable of metabolic inversion to the corresponding (+)enantiomers; 
this unidirectional bioinversion has been suggested for the predominance 
of the (+)enantiomer in plasma and urine following administration of the 
racemate or (-)ibuprofen (Vangiessen and Kaiser, 1975; Mills et al.. 
1973).
CH3 CH3
2,CH-CH2— — CH-COOH
ch3
IBUPROFEN CICLOPROFEN
Enantiomeric differences in drug toxicity have also been reported 
(Hall, 1977; He Oong, 1977).
The anti-angina drug, perhexiline, is chiral owing to asymmetry at 
C-2 (Fig, 5.1). The drug is used clinically as a racemate of (+) and
CH-COOH
(-)perhexiline maleate (Pexid). The (+) and (-)enantiomers of perhexiline 
are equi-active with respect to coronary vasodilator activity in 
anaesthetized dogs (Burke, 1982). In view of the reported toxicity 
(Fraser and Miller, 1978; Leutenegger, et al,, 1976; Daly, jet jal., 1977; 
Stentiford, 1977; Lubetzki, jet aJL., 1977; Blanchion jit .al,, 1977) and 
the observed stereoselective metabolism of the racemate in humans 
(Chapter 4), an oral cross-over study of the resolved enantiomers was 
undertaken in 8 healthy young adult volunteers to elucidate the nature of 
disposition and pharmacokinetics of perhexiline enantiomers.
EXPERIMENTAL
CLINICAL STUDY
Eight normal and healthy young adults aged 23 - 34 years, screened 
previously as described in Chapter 4, were given 300 mg (+)Pexid tablets, 
and blood and urine samples collected as described previously in Chapter 4. 
Three to four weeks later, the study was repeated with (-)Pexid tablets. 
Plasma and urine samples were stored and analysed as described previously 
in Chapter 2. The (+)Pexid and (-)Pexid tablets were gifts from Merrell- 
Dow Pharmaceuticals Limited, U.K.
PHARMACOKINETIC AND STATISTICAL ANALYSIS
The pharmacokinetic procedures described in Chapter 4 were employed 
in the analysis of.data. Student's t-test for paired data was used to 
calculate significant differences between means. A significant 
difference was taken as P ^ 0.05.
RESULTS
The plasma perhexiline and metabolite-time profiles and the 
corresponding cumulative urinary metabolite excretion in the 8 
healthy young subjects following administration of perhexiline 
enantiomers (300 mg) are shown in Figures 5*2 - 5.9. The daily 
output of urine after ingestion of (+) and (-)Pexid is shown in 
Figure 5.10. In Figures 5.H - 5.18, the plasma perhexiline (top) 
and cis-monohydroxy-perhexiline (bottom)-time profiles,following 
administration of the racemate (Chapter 4) and the resolved enantiomers 
are compared. The characteristics of subjects taking part in the study 
are shown in Table 5.1. Pharmacokinetic parameters following administration 
of (+) and (-)Pexid are summarised in Tables 5.2 and 5.3 respectively; 
the corresponding urinary excretion data are reported in Table 5.4 and 
5.5. In Table 5.6 pharmacokinetic and urinary excretion data of the 
resolved enantiomers are compared; racemate data are compared with those 
of (+) and (-)Pexid in Tables 5.7 and 5.8 respectively.
ENANTIOMERIC DIFFERENCES
Consistently, (+)perhexiline produced higher plasma unchanged- 
perhexiline concentrations than its optical antipode. After administration 
of the (+)enantiomer.* plasma trans-monohydroxy—perhexiline levels were 
either higher or about equal to those of its cis-diastereomer and plasma 
metabolite levels were always lower than those of unchanged perhexiline.
In contrast, following the ingestion of the (-)enantiomer, plasma trans- 
monohydroxy-perhexiline was either very low or was undetectable, and 
plasma cis-monohydroxy-perhexiline levels were always markedly higher 
than those of unchanged perhexiline (Fig. 5.2- 5.9 (top)).
Peak plasma concentrations of perhexiline following ingestion of 
the (+) and (—)enantiomers occurred about the same time (6,0 — 0,9 and 
6,3 -* 0.8 respectively) (see Table 5*2 and 5.3). The mean peak plasma 
concentration of unchanged perhexiline after ingestion of the 
(+)enantiomer was 2.6 times greater than after ingestion of its optical 
antipode. The AUC of plasma perhexiline upon oral administration of 
(+)perhexiline was about three times that after administration of 
(-)perhexiline.
Plasma peak cis-mouohydroxy—perhexiline concentration occurred . 
slightly later with the (-) than with (+)enantiomer; the difference 
in peak times, however, was not statistically significant (Table 5.6).
The AUC of plasma cis-monohydroxy-perhexiline following administration 
of the (-)enantiomer was 25 times greater than that after administration 
of the (+)-enantiomer; in contrast, the AUC of the plasma trans- 
monohydroxy-diastereomer was 9 times greater after the (+)enantiomer 
than after the (-)enantiomer. The plasma elimination half-lives of 
perhexiline following administration of the two enantiomers, were however, 
about the same (Table 5.6).
Following oral administration of (+)perhexiline, trans-monohydroxy- 
perhexiline constituted the predominant perhexiline-metabolite in the 
urine with a mean trans- to cis-diastereomeric ratio of 5.3 — 1.7. In 
contrast, cis-monohydroxy-perhexiline was the major urinary metabolite 
following ingestion of the (-)enantiomer of perhexiline. Of the orally 
administered dose of (+) and (-)perhexiline, 6 and 19$ respectively were 
excreted in the urine as metabolites at the end of 5 days (Table 5.6;
Figs. 2 - 9  (bottom).
RACEMATE AND ENANTIOMERS
There was no statistical difference between (+)perhexiline and the 
racemate with regards to peak plasma perhexiline time, time to peak 
pla sma cis-monohydroxy-perhexiline concentration and plasma perhexiline 
elimination half-life. Peak plasma perhexiline concentration and AUC 
of plasma perhexiline were about twice as great following the administration 
of the (+)enantiomer than following the administration of racemic 
perhexiline. Peak plasma cis-monohydroxy-perhexiline level and AUC of 
the cis-diastereomer were respectively 9 and 1 3 times greater after 
ingestion of the racemate than after ingestion of the (+)enantiomer.
A greater percentage of the administered dose of the racemate than of 
the (+)enantiomer was eliminated in the urine as monohydroxy-perhexilines 
(Table 5.7).
There was no statistical difference between the racemate and 
(-)perhexiline with respect to time to peak plasma perhexiline concentration, 
peak plasma perhexiline concentration, time to peak plasma cis-mono­
hydroxy-perhexiline concentration and plasma elimination half-life of 
perhexiline (Table 5.8). The AUC of perhexiline following the 
administration of racemic perhexiline was about one and a half times 
that of the (-)enantiomer. Peak plasma cis-monohydroxy-perhexiline 
concentration and the AUC of cis-metabolite were twice as great after 
the (-)enantiomer than after administration of the racemic mixture. 
Relatively more trans-metabolite was excreted in the urine with the 
racemate than with the (-)enantiomer; however, the major metabolite 
with both dosage forms was the cis-perhexiline diastereomer. The 
cumulative urinary metabolite excretion were 11.94 6.1$ and 19.3 — 7.1$
of the administered dose for the racemate and (-)enantiomer respectively 
(Table 5.8).
In seven subjects, plasma unchanged perhexiline levels were highest 
with (+)Pexid, and least with (-)Pexid, with those of the racemate being 
intermediate (Figures 5.H, 5.12 and 5.14 - 5.18 (top). In an eighth 
subject (H.L.), the lowest plasma perhexiline levels in contrast, 
followed the administration of the racemate with the highest levels 
again associated with the administration, of the (+)enantiomer (Figure 5.13 
(top)). Cis-monohydroxy-perhexiline levels following the administration 
of racemic perhexiline were intermediate between those following the 
administration of the resolved enantiomers in all subjects; the highest 
cis-metabolite levels occurred after ingestion of the (-)enantiomer 
(Figures 5.H - 5.18 (bottom)).
DISCUSSION
In the present study, stereoselective differences in the bio­
transformation of perhexiline enantiomers were observed. After oral 
administration of equivalent doses of the enantiomers, significantly more 
unchanged drug was available in the systemic circulation with the (+) 
enantiomer than with its optical antipode. More extensive presystemic 
drug metabolism followed the administration of the (-)enantiomer than the 
(+)enantiomer; all subjects metabolized the (-)enantiomer at a faster rate 
than either the racemate or the (+)enantiomer. The metabolism of the 
racemate was in turn, more rapid than that of the (+)enantiomer.
Following drug administration, cis-hydroxylation of perhexiline 
was the preferred biotransformation pathway with the (-)enantiomer; 
in contrast, trans-hydroxylation of perhexiline was the predominant 
route of metabolism after administration of the (+)enantiomer. Thus the 
predominance of cis-monohydroxy-perhexiline in the blood and urine
following administration of racemic perhexiline (Chapter 4) was largely 
due to metabolism of the (-)enantiomer„ A greater percentage of the 
oral dose was excreted in the urine as cis- and trans-monohydroxy- 
perhexilines following administration of (-) rather than (+)perhexiline.
There was no significant difference in the plasma elimination half- 
lives of the two enantiomers. A more sensitive indicator of drug 
elimination is, however, the systemic clearance (Wilkinson and Shand, 
1975? Rawlins, 1980). The systemic clearance of either perhexiline 
enantiomers could not however be calculated as the systemic bio- 
availability^)!^these dosage forms were not determined for practical 
reasons. If one, however, assumes equivalent bioavailabilities for 
the two—Pexid enantiomers (identical formulations), the greater AUC 
of (+) than (-)enantiomer will imply a greater clearance of the 
(-)enantiomer; one must however bear in mind the influence of pre- 
systemic drug elimination in estimations of systemic drug clearance 
(Rawlins, 1980).
From the AUC and urinary excretion data, drug accumulation on 
prolonged Pexid therapy is more likely to occur with the (+) than with 
either the (-)enantiomer or racemic mixture, and least likely with 
(-)Pexid.
The dramatic changes in urine output observed after administration 
of the racemate (Fig. 4.9) were not evident on administration of either 
enantiomer (Fig. 5.l0«).In 6 subjects (R.O., Y.L„, H.L., N.G., A.D., 
and S.P.) urine output were generally higher after the (-)isomer than 
after the (+)enantiomer. More properly designed studies are clearly 
needed to evaluate the enantiomeric differences in diuresis and other
pharmacological actions of perhexiline, including efficacy in anti- 
angina prophylaxis.
The results of the present study indicate significant stereo­
selectivity in perhexiline disposition and metabolism. Perhexiline 
enantiomers exhibited both substrate and substrate-product stereo­
selective metabolism. Further studies are needed to delineate factors 
which govern the stereoselective disposition of the drug and the 
influence of multiple dosing on enantiomeric differences, in view of 
the significant toxicity of the racemate in humans, with the ultimate 
objective of deciding if either enantiomer could suitably replace the 
racemate in the treatment of angina pectoris.
Figure 5.1« Stereoselective metabolism of perhexiline
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on metabolism,
+ asymmetric centre
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Figure 5«2C Stereoselective pharmacokinetics of Perhexiline
Time course of plasma perhexiline and monohydroxy-perhexiLines 
following oral administration of (+) and (~) Pexid tablets 
(300 mg) in a young healthy adult volunteer and the corresponding 
cumulative urinary metabolite excretion (note difference in the 
scales on the ordinates); subject R.O.
▲ cis—metabolite; ■ trans-metabolite;
• unchanged perhexiline
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Figure 5*3* Stereoselective pharmacokinetics of perhexiline
Time course of plasma perhexiline and monohydroxy-perhexilines 
following oral administration of (+) and (-) Pexid tablets 
(300 mg) in a young healthy adult vohmteer and the corresponding 
cumulative urinary metabolite excretion (note difference in 
scales on the ordinates); subject S.G.; Key to symbols as in
Figure 5*2„
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Figure 5.k* Stereoselective pharmacokinetics of perhexiline
Time course of plasma perhexiline and monohydroxy-perhexilines 
following oral administration of (+) and (-) Pexid tablets 
(300 mg) in a young healthy adult volunteer and the corresponding 
cumulative urinary metabolite excretion (note difference in the 
scales on the ordinates):
subject H.L.; Key to symbols as in Figure 5.2.
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F i g u r e  5.5„ S t e r e o s e l e c t i v e  p h a r m a c o k i n e t i c s  oi p e r h e xiline
Time course of plasma p e r h e xiline and m o n o h y d r o x y - p e r h e x i l i n e s  
f o l l o w i n g  oral a d m i n i s t r a t i o n  of (+) and (-) Pexid tablets  
(300 mg) in a y o u n g  hea l t h y  a d u l t  v o l u n t e e r  and the c o r r e s p o n d i n g  
cumulative uri n a r y  m e t a b o l i t e  e x c r e t i o n  (note d i f f e r e n c e  in 
scales 011 the ordinates); subject N.G.; key to symbols as in
F i g u r e  5.2.
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Figure 5.6. Stereoselective pharmacokinetics of perhexiline
Time course of plasma perhexiline and monohydroxy-perhexiline 
following oral administration of (+) and (-) Pexid tablets 
(300 mg) in a young healthy adult volunteer and the corresponding 
cumulative urinary metabolite excretion (note difference in 
scales on ordinates); subject A.D.; Key to symbols as in
Figure 5.2.
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Figure 5.7. Stereoselective pharmacokinetics of perhexiline
Time course of plasma perhexiline and monohydroxy-perhexilines 
following oral administration of (+) and (—) Pexid tablets 
(300 mg) in a young healthy adult volunteer and the corresponding 
cumulative urinary metabolite excretion (note difference in the 
scales on the ordinates); subject J.B.; key to symbols as in
Figure 5.2.
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Figure Stereoselective pharmacokinetics of perhexiline
Time course of plasma perhexiline and monohydroxy-perhexilines 
following oral administration of (+) and (~) Pexid tablets 
(300 mg) in a young healthy adult volunteer and the corresponding 
cumulative urinary metabolite excretion (note difference in the 
scales on the ordinates); subject Y.L.; key to symbols as in
Figure 5.2*
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Figure 5.9. Stereoselective pharmacokinetics of perhexiline
Time course of plasma perhexiline and monohydroxy-perhexiline 
following oral administration of (+) and (-) Pexid tablets 
(300 mg) in a young healthy adult volunteer and the corresponding 
cumulative urinary metabolite excretion (note difference in the 
scales on the ordinates); subject S.P.; key to symbols as in
Figure 5.2.
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Figure 5.10. Enantiomeric differences in urine output
Urine output following ingestion of (+) and (-) fexid tablets 
(300 mg) in 8 healthy young adult volunteers.
a H.L. □ A.D.
A Y.L. • S.G.*
* N.G. ■ J.B.
o R.O. S.P.
*Drank alcoholic beverages from the second day onwards.
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TABLE 5.1.
Human volunteers participating in stereoselective
pharmacokinetics study of perhexiline
Subject Sex Age
(yr)
Body Weight
(Kg)
Dose of (+) or 
(-)Pexid (mg/Kg)
R.O. Female 27 57 5.3
Y.L. Female 28 47 6.3
H.L. Female 23 50 6.0
N.G. Female 25 43 7.0
a .d . Male 31 55 5.4
J «B • Male 34 83 3.6
S.G. Male 23 68 4.4
S.P. Male 30 68 4.4
Mean 27.6 58.9 5.3
S.E.M. 1.4 4.7 0.4
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Table 5.6.
Comparison of pharmacokinetic and urinary excretion data following 
administration of (+) and (-) Pexid tablets (300 mg) in human 
volunteers; PX = perhexiline; = cis-metabolite;
= trans-metabolite. Values are means £ S.D.; n = 8 except 
for * when n = 7; S = Significant; NS = Not Significant.
Parameter (+) Pexid (-) Pexid Significance
Peak plasma PX time (hour) 6.0 + 2.6 6.3 £ 2.3 NS
*Peak plasma M-^  time (hour) 5.4 - 2.8 8.3 £ 2.9 NS
Peak plasma PX concentration 230 £ 110 90 £ 50 S
(ng ml”1) (p x  0.01)
*Peak plasma concentration s
(ng ml”1) 52 - 13 970 £ 360 (p <  0.001)
AUC - PX 5700 £ 4600 1900 £ 1600 s
(ng.h. ml”1) (p <  0.01)
*AUC - M 910 £ 300 22000 £ 6500 s
(ng.h. ml”1) ( p <  0.001)
AUC - 1320 £ 1040 150 £ 190 s
(ng.h. ml”1) (p <  0.001)
Plasma PX t\ (hour) 13.6 £ 6.0 12.5 £ 6.8 NS
Urinary M^/M^ ratio 5.3 £ 1.7 0 .3 £ 0.1 s
(p <  0.001)
Metabolite exc<retion 5.6 £ 4.1 19.3 £ 7.1 0
$ of dose (p <  0.001)
Table 5«7«
Comparison of pharmacokinetic and urinary excretion data following
administration of (+) and racemic Pexid tablets (300 mg) in human 
volunteers; PX = perhexiline; M-^  = cis-metabolite; = trans­
metabolite. Values are means - S.D.; n = 8 except for * when 
n = 7; S = significant: NS = not significant.,
Parameter (+) Pexid Eacemate Significance
Peak plasma PX time (hour) 6.0  -  2.6 6 .5  -  2.1 NS
*Peak plasma time (hour) 5.4 -  2,8 7.4 i  2.2 NS
Peak plasma PX concentration 230 i  1X0 110 -  60 S
(ng ml”1) (p <£ 0 . 01)
*Peak plasma concentration 52 -  13 470 -  130 s
(ng ml"1) (P <  0 . 001)
AUC - PX 5700 i  4600 2800 -  1700 s
(ng.h ml 1) (p <  0.05)
*AUC - M 910 i  300 12000 -  3900 s
(ng.h ml"1) (p <  0 .001)
Plasma PX tjr (hour) 13.6 ~ 6,0 14.2 ± 5.5 NS
Urinary M_/M, ratio 5.3  -  1.7 0.5 -  0.2 s
(p <  0.001)
Metabolite excretion 5.6 i  4.1 11.9 - 6.1 s
of dose (p <  0 .01)
Table 5.8.
Comparison of pharmacokinetic and urinary excretion data following
administration of (-) and racemic Pexid tablets (300 mg) in human
volunteers; PX = perliexiline; == cis-metabolite; = trans-
metabolite. Values are means - S.D.; n = 8 except for * when 
n = 7.
Parameter (-) Pexid Racemate Significance
Peak plasma PX time (hour) 6.3 - 2.3 6.5 - 2.1 NS
*Peak plasma time (hour) 8.3 - 2.9 7.4 i 2.2 NS
Peak plasma PX concentration 90 i 50 110 i 60 NS
(ng ml”1)
*Peak plasma concentration 970 i 360 470 i 130 S
(ng ml”1) (p ^  0.01)
AUC - PX 1900 i 1600 2800 i 1700 s
(ng h. ml 1) (p <  0.001)
*AUC - H 22000 - 6500 12000 i 3900 s
(ng h. ml”1) ( p ^  0.01)
Plasma elimination half-life
of PX (hour) 12.5 - 6.8 14.2 i 5.5 NS
Urinary M^/M^ ratio 0 .3 i 0.1 0.5 - 0.2 s
(p <  0.01)
Metabolite excretion 19.3 - 7.1 19.3 - 7.1 s
'jo of dose ( p <  0 .01)
CHAPTER 6
IN VITRO HEPATIC MICROSOMAL 
METABOLISM OF PERHEXILINE
INTRODUCTION
The mechanism of perhexiline-induced toxicity in humans is not 
very clear. Impaired drug metabolism with resultant toxic drug cumulation 
has been implicated in at least perhexiline-induced peripheral neuropathy, 
(Singlas, et al,, 1978), Genetic polymorphic oxidation of debrisoquine 
(Maglioub, ejfc a^ L., 1977; Mbanefo, ejt aJL,, 1980), phenformin (idle and 
Islam, 1981), and sparteine (Eichelbaum, _et al9, 1979) have recently 
been reported in humans. Individuals with impaired capacity to metabolize 
these drugs (poor metaboliser or PM phenotype), comprising 1 - 9$ of 
most populations studied, are more likely to accumulate these drugs in the 
body to toxic levels than individuals with normal oxidative drug metabol­
izing capacity (extensive metabolizer or EM phenotype). Shah et al (1982) 
have recently demonstrated a clear association between impaired drug 
metabolic capacity, as shown by debrisoquine hydroxylation, and perhexiline- 
induced peripheral neuropathy.
The molecular mechanism of the genetically determined impairment in 
drug oxidation is, however, not fully understood. Some manner of 
dysfunction of the liver microsomal mono—oxygenase system has been 
implicated. Liver microsomes from a PM subject, despite normal cyto­
chrome P-450 content, failed to hydroxylate debrisoquine compared to 
microsomal preparations from EM subjects (Davies, et al., 1981).
Animal models representing the PM (inbred female DA rat strain) and 
EM (inbred female Lewis rat strain) human phenotypes have recently been 
reported (Al-Dabbagh, _et al,, 1981).
In the present study, the In vitro liver microsomal hydroxylation
of perhexiline was characterized in the Wistar albino rat, and enzyme 
kinetic studios carried out in the Wistar, Lewis and DA rats. The 
stereoselective metabolism of racemic, (+) and (-) perhexiline by 
Wistar, Lewis and DA rat hepatic microsomes, and microsomes from human 
liver biopsy specimens, were subsequently investigated.
MATERIALS AND METHODS
CHEMICALS
NADPH was obtained from Sigma (Poole, Dorset, U.K.). .Bacemic,
(+) and (—) perhexiline maleate and cis- and trans-monohydroxy-perhexiline 
were gifts from Merrell National Laboratories (Cincinnati, Ohio, U.S.A.). 
All other chemicals were analytical grade or as specified in Chapter 2.
ANIMALS
Male Wistar albino (University of Surrey, Guildford, U.K.), female 
Lewis (Bantin and Kingman, Hull, U.K.) and female DA (Bantin and Kingman, 
Hull, U.K.) rats weighing 150 - 180g were used. Animals were allowed 
food (Spratts Animal Diet No. l) and water ajd libitum.
PREPARATION OF MICROSOMES
Rats were killed by cervical dislocation at 10 - 11a.m., the livers 
excised rapidly and placed in ice-cold 1.15$ (w/v) KC1. The livers were 
then washed, blotted dry and weighed. Subsequent operations were carried 
out at 0 - 4°C. The livers were scissor minced and homogenized in 
4 volumes of 1.15$ (w/v) KC1 with three return strokes of the pestle in 
a Potter-Elvehjem glass-Teflon homogenizer (size C, A.H. Thomas and Co., 
Philadelphia, U.S.A.). The homogenate was centrifuged at 10,000g for
20 min in an MSE "High Speed 18" refrigerated centrifuge. The resultant 
supernatant was further centrifuged at 105,000g for 1 hour in a Beckman 
ultracentrifuge (Model LS-65). The supernatant was discarded and the 
microsomal pellet washed in 1.15$ (w/v) KC1. The washed pellet was 
resuspended in the same volume of homogenizing medium and centrifuged 
again under the same conditions. The pellet was finally washed and 
suspended (lg liver - 1 ml buffer) in 0.1M potassium phosphate buffer 
(pH 7*6) containing 20$ glycerol, ImM EDTA and ImM dithiothreitol; 
the microsomal suspension was stored at -80°C and used within a month 
of storage.
PROTEIN DETERMINATION
Microsomal protein content was determined by the method of Lowry,
_et _al,, 1951 using bovine serum albumin as standard.
Reagents: 50 mM NaOH
1$ (w/v) hydrated copper sulphate 
2$ (w/v) sodium potassium tartrate 
50 mM NaOH containing 2$ (w/v) sodium carbonate 
Folin-Ciocalteau phenol reagent diluted with water (l:2(v/v))
Method:
Microsomal samples were diluted with 50 mM NaOH to give a protein 
concentration of less than 250 fig/ml (normally a final dilution of 1 in 
200). The protein standard was diluted with 50 mM NaOH to give 
concentrations of 50, 100, 150, 200 and 250 jjg/ml. The copper sulphate, 
sodium potassium tartrate and sodium carbonate solutions were mixed in 
the ratio 1:1:100 by volume (copper reagent) immediately before use.
The diluted microsomal samples, protein standards and blanks (0,5 ml) 
were mixed with the copper reagent (5.0 ml) and allowed to stand for 
10 min at room temperature before addition of the diluted Folin-rCiocalteau 
reagent (0.5 ml) with immediate mixing. After at least 30 min at room
temperature, the absorbance at 720 nm was recorded in a Cecil 272 linear 
readout spectrophotometer (Cecil Instruments, U.K.).
CYTOCHROME P-450 DETERMINATION
The method of Sladek and Mannering (1966) was used. Microsomal 
suspension (25$) was diluted three-fold with 0 .1M phosphate buffer 
(pH 7*4) and the diluted suspension (5 ml) divided equally between two 
1 cm glass cuvettes. A baseline of equal light absorbance between 
400 - 500 nm was recorded with the Cary 219 Spectrophotometer in dual 
beam mode, and the contents of both cuvettes reduced by addition of 
( 1 - 2  mg) of solid dithionite. Carbon monoxide was then bubbled 
through the contents of the sample cuvette for 20 seconds and the 
difference spectrum recorded between 400 - 500 nm. The djsorbance 
maximum (450 nm) was measured relative to that at 490 nm and the 
concentration of cytochrome P-450 calculated using an extinction 
coefficient of 91 mM 1 cm 1 (Omura and Sato, 1964).
ENZYME ASSAY
Optimum conditions of hepatic microsomal hydroxylation of perhexiline 
were investigated in the Wistar rat by varying in turn, the pH, the time 
of incubation, the concentration of NADPH, MgCl^, microsomal protein 
and racemic perhexiline, A standard assay contained 0.4 ml microsomal 
suspension (25$), 0.25 ml NADPH (6 mM), 0.25 ml MgC.lg (40 mM), 8 |_il 
Perhexiline in methanol (50 mM) and 1.09 ml potassium phosphate buffer, 0. 
(pH 7.4). Following a 2 min pre-incubation at 57°C in a shaking water- 
bath, the reaction was initiated by the addition of microsomes. At the 
end of 5 min incubation, the reaction was terminated by the addition of 
6M HC1 (0.5 ml). Reaction blanks were prepared by addition of perhexiline
after termination of incubation; reference standards containing trans- 
monohydroxy- (2.8 - 24.0 {jM) and cis-monohydroxy- (0.6 - 11.6 jjM) 
perhexiline were similarly prepared.
H.P.L.C. ANALYSIS
Following the addition of 4M NaOH (l ml) blank, test and standard 
samples were extracted with 15 ml diethyl ether for 1 hour. After 
separation of the phases, the ether layer was evaporated to dryness and 
the residue derivatized and analysed by h.p.l.c. as described previously 
(Chapter 2).
EFFECT OF CARBON MONOXIDE
The effect of carbon monoxide on microsomal hydroxylation of 
perhexiline was investigated by bubbling carbon monoxide through the 
incubation mixture for 15 seconds prior to incubation under optimum 
conditions.
ENZYME KINETICS
Hepatic microsomes from male Wistar, female Lewis and female DA
rats were incubated in the presence of 10 - 150 pM racemic perhexiline
using standard assay conditions. The apparent V and 1C were obtainedmax m
by employing a regression computer program that utilizes biweighting to 
achieve robustness against outliers (Cornish-Bowden and Endrenyi, 1981).
-f
Values are means - S.E.M.
STEREOSELECTIVE METABOLISM
Hepatic microsomes from male Wistar, female Lewis and DA rats and
microsomes from three human liver biopsy specimens were incubated in the 
presence of racemic (+) and (-) perhexiline (100 pM) using standard assay 
conditions. The monohydroxy-perhexilines formed were measured as described 
above.
STATISTICAL ANALYSIS
Reported values are means - S.E.M. for assays on hepatic microsomal 
preparation from 4 rats or three human subjects. Student’s t—test for 
unpaired data was used to calculate significant differences between 
results.
RESULTS
REACTION CHARACTERISTICS
Beer's law plots obtained by addition of reference cis- and trans- 
monohydroxy-perhexilines to control liver microsomes are shown in 
Figure 6.1, The DA rat had the highest content of microsomal protein 
per gram liver. There was not much difference between the three rat 
strains with regard to microsomal cytochrome P-450 content (Table 6.1). 
Figures 6.2 to 6.10 show the profiles of the reaction characteristics 
of rat (Wistar) hepatic microsomal hydroxylation of perhexiline. Optimum 
reaction conditions for microsomal hydroxylation of perhexiline by 
Wistar rat hepatic microsomes are summarised in Table 6.2.
Racemic perhexiline was metabolized to cis- and trans-monohydroxy-
perhexilines by rat liver microsomes with trans-hydroxylation of
perhexiline as the major pathway. The iri vitro hepatic microsomal
2+perhexiline metabolism was dependent on NADPH and Mg • Optimum
2+concentrations of NADPH and Mg for perhexiline hydroxylation were 0.15 - 
0.75 mM and 3mM respectively (Figures 6.2 and 6.3). Boiling microsomes
prior to incubation with perhexiline resulted in complete loss of 
hydroxylase activity. Both cis- and trans- hydroxylation of 
perhexiline were linear up to 5 minutes; a plateau in the progress 
curve was reached when only 0.002 and 0.007 per cent of substrate had 
been converted to cis- and trans-metabolite respectively (Figure 6.4 
and 6.5)* Metabolite formation was proportional to the concentration 
of enzyme up to 1 mg microsomal protein/ml incubate (Figure 6.6 and 6.7)* 
Microsomal metabolism of perhexiline was not significantly pH dependent 
in the pH range 7*4 - 8.0 (Figure 6.8), Bubbling carbon monoxide through 
the reaction mixture for 1 5 seconds prior to incubation resulted in 88^ 
and 90$ reduction in the yield of cis- and trans- monohydroxy-perhexilines 
respectively, compared to control microsomes (Table 6.3). Michaelis 
plots of cis- and trans— hydroxylation of perhexiline yielded hyperbolic 
curves (Figures 6.9 and 6.10).
STRAIN DEPENDENT ENZYME KINETICS
The Lineweaver-Burk plots of experimental data and computer weighted 
data of the three rat strains are shown in Figures 6.11 — 6.13. The 
computed weighted Lineweaver-Burke plots of the three rat strains with 
regards to cis- and trans- hydroxylation of perhexiline are compared in 
Figures 6.14 and 6.15 respectively. In all rat strains, the experimental 
data for both cis- and trans-hydroxylation of perhexiline yielded concave 
downward Lineweaver-Burk plots with the curvature being more marked for 
trans- than cis- hydroxylation. The computer weighted data gave the best 
straight line (Figures 6.11 — 6.13). The extrapolated lines of the 
computer generated linear regression lines for cis- and trans- hydroxylation 
of Wistar and Lewis rats met the ordinate (l/v axis); the corresponding 
extrapolated lines of the DA rat, in contrast, met the abscissa (l/s axis) 
(Figures 6.14 and 6.15).
In all three strains of rats, trans-hydroxylation proceeded at a
faster rate than cis-hydroxylation; trans- to cis-metabolite ratios
are shown in Table 6.4. The computer estimated apparent V and Kmax m
of the three rat strains for cis- and trans-hydroxylation of perhexiline 
are shown in Table 6.5. The apparent V y and Km for cis-hydroxylation 
for Wistar and Lewis rats were about the same. There were, however, 
significant differences between ihe irw-ostrains with regard to apparent 
trans-hydroxylation V .^ and Km . In the DA rat, microsomal hydroxylation 
of perhexiline gave negative apparent V Y and Km values for both cis- 
and trans-hydroxylation (Table 6.5).
STEREOSELECTIVE PERHEXILINE METABOLISM
When racemic perhexiline (50 pM of each enantiomer) was incubated 
with liver microsomes from Wistar, Lewis and DA rats, transhydroxylation 
was the predominant pathway of perhexiline metabolism (Table 6.6). The trans- 
to cis-monohydroxy-perhexiline ratio following microsomal metabolism of 
racemic perhexiline in Wistar, Lewis and DA rats were 4.44 i 0.24,
5.44 i 0.23 5.97 - 0.40 respectively (Table 6.7). Both cis- and
trans-hydroxylation occurred more rapidly in the normally hydroxylating 
rat microsomes (Wistar and Lewis) than in the hydroxylation deficient rat 
microsomes (DA) (Table 6.6).
When (+) and (-) perhexiline (100 pM) were incubated separately 
with microsomes, the (—) enantiomer was metabolized more rapidly than 
its optical antipode in all rat strains. Trans-hydroxylation of (-) 
perhexiline was about 3 and 6 times greater than that of (+) perhexiline 
in normal (Wistar and Lewis) and abnormal (DA) microsomes respectively.
In contrast, cis-hydroxylation of (-) perhexiline was only 2 and 3 times 
greater than that of (+) perhexiline in normal and abnormal microsomes
respectively (Table 6,6). The rate of metabolism of the racemate was 
lower than that of the (-) enantiomer but greater than that of the (+) 
enantiomer (Table 6,6).
There was no statistically significant difference in perhexiline 
metabolism between Wistar and Lewis rats (Table 6.8). Significant 
differences in metabolism between Lewis and DA rat microsomes were 
observed for the Jri vitro metabolism of racemic and (+) perhexiline; 
for the (-) enantiomer, the difference between these two strains with 
regard to cis- but not trans-hydroxylation was statistically 
significant (Table 6.9)* Significant differences in hydroxylation of 
perhexiline between Wistar and DA rats were observed except for trans- 
hydroxylation of racemic and (-) perhexiline (Table 6.10).
The pattern of perhexiline metabolism in human microsomes was 
different from that seen in rat microsomes. In human microsomes the 
rate of cis-hydroxylation of racemic perhexiline was only marginally 
(not statistically significant) greater than trans-hydroxylation; 
trans-hydroxylation was marginally (no statistical significance) greater 
than cis-hydroxylation when human microsomes were incubated with (+) 
perhexiline. In the presence of (-) perhexiline, cis-hydroxylation 
became the predominant metabolic pathway (Table 6.11).
DISCUSSION
The cytochrome P-450-dependent mono-oxygenase system, present in 
liver microsomes, is capable of metabolizing a wide variety of drugs and 
other xenobiotics (Parke, 1981). The in vitro activity of this mixed- 
function oxidase system requires the presence of viable microsomes, 
NADPH—regenerating system or NADPH itself, and molecular oxygen (Mueller
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Figure 6.1, Beer's law plot showing peak heights for recovery of added
cis- and trans-hydrox.y-perhexiline from liver microsomes
Samples were derivatized and analysed hy h.p.l.c. as described 
in Chapter 2.
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Figure 6.2. NADPH dependence
In vitro hepatic microsomal metabolism of perhexiline in Wistar 
rats. Reaction mixture containing 200 (jM racemic perhexiline,
5 mM Mg^+, 0.1M potassium pliasphate buffer (pH 7e4), microsomal 
protein (0.5 - 0.8 mg/ml) and NADPH in a final volume of 2 ml 
was incubated at 37°C for 5 minutes. (4 animals)
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Figure 6,3. Mg dependence
In vitro liver microsomal metabolism of perhexiline in Wistar
Rats, Reaction mixture containing 200 (jM racemic perhexiline,
1,5 niM NADPH, microsomal protein (0,5 - 0,8 mg/ml) and 0,1M
2+potassium phosphate buffer (pH 7.4) and Mg in a final volume 
of 2 ml was incubated at 37°C for 5 minutes, (4 animals)
■ trans-metabolite 
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Figure 6.4. Progress curve
Cis-hydroxylation of perhexiline in vitro by liver microsomes 
from Wistar rats. Reaction mixture contained 200 (jM racemic 
perhexiline, 1.5 mM NADPH, 5 mM Mg^+, 0.5 - 0.8 mg/ml 
microsomal protein and 0.1M potassium phosphate buffer 
(pH 7.4) in a final volume of 2 ml was incubated at 37°C.
(4 animals)
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igure 6.5. Progress curve
Trans-hydroxylation of perhexiline Jji vitro by liver microsomes 
prepared from Wistar rats. Reaction mixture containing 200 (jM 
racemic perhexiline, 1,5 mM NADPH, 5 mM Mg^+, 0.5 - 0.8 mg/ml 
microsomal protein and 0.1M potassium phosphate buffer 
(pH 7.A) in a final volume of 2 ml was incubated at 37°C.
(4 animals)
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Figure 6,6. Protein dependence
In vitro liver microsomal trans-hydroxylation of perhexiline in
Wistar rat. Reaction mixture containing 200 (jlM perhexiline
2+
(racemate), 1.5 mM NADPH, 5.0 mM Mg , 0*1 M potassium 
phosphate buffer (pH 1,h) and microsomal protein in a final 
volume of 2 ml was incubated at 37°C for 5 minutes.
(4 animals)
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Figure 6,7. Protein dependence
In vitro liver microsomal cis-hydroxylation of perhexiline in
Wistar rat. Reaction mixture containing 200 [jM perhexiline 
/ \ 2+(racemate), 1,5 mM NADPH, 5 mM Mg , 0,1M potassium phosphate 
buffer (pH 7.^) and microsomal protein in a final volume of 
2 ml was incubated at 37°C for 5 minutes,
(4 animals)
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Figure 6.8. pH dependence
In vitro liver microsomal metabolism of perhexiline in Wistar 
rats. Reaction mixture containing 200 pM racemic perhexiline
1.5 mM NADPH, 5 mM Mg , 0.5 - 0.8 microsomal protein/ml in a 
final volume of 2 ml was incubated at 37°C for 5 minutes.
(4 animals)
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Figure 6.9. Michaelis plot
Cis-hydroxylation of perhexiline in liver microsomes prepared 
from Wistar rats. Reaction mixture containing 1.5 mM NADPH, 
5.0 mM Mg^+, 0.1M potassium phosphate buffer (pH 7.z0» 
microsomal protein (0.5 - 0.8 mg/ml) and perhexiline 
(10 - 150 pM) in a final volume of 2 ml was incubated at 
37°C for 5 minutes.
(4 animals)
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Figure 6.10. Micliaelis plot
Trans-hydroxylation of perhexiline in liver microsomes 
prepared from Wistar rats. Reaction conditions as in 
Table 6.5. (*i animals)
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Figure 6.11. Enzyme kinetic study
Lineweaver-Burk plots of the cis- and trans-hydroxylation 
of perhexiline by hepatic microsomes prepared from Wistar 
rats (4 animals). Assay conditions as in Table 6.5. The 
experimental values are given together with computer 
weighted straight lines giving the corresponding theoretical 
points.
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Figure 6,12. Enzyme kinetics
Lineweaver-Burk plots of the cis- and trans-hydroxylation 
of perhexiline by liver microsomes prepared from Lewis 
rats (4 animals). Assay conditions as in Table 6.5* The 
experimental data are given together with the computer 
weighted straight lines giving the corresponding theoretical 
points.
* cis-hydroxylation - computer weighted data
° cis-hydroxylation - experimental data
* trans-hydroxylation - computer weighted data
a trans-hydroxylation — experimental data
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Figure 6,13, Enzyme kinetics
Lineweaver-Burk plots of cis- and trans-hydroxylation of 
perhexiline by hepatic microsomes prepared from DA rats 
(4 animals). Assay conditions as in Table 6.5. The 
experimental values are given together with the computer 
weighted straight lines giving the corresponding theoretical 
points. ~
* cis-hydroxylation - computer weighted data
o cis-hydroxylation - experimental data
♦ trans-hydroxylation - computer weighted data
a trans-hydroxylation - experimental data
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Figure 6,14. Enzyme kinetics
In vitro liverjmicioeomal cis-hydroxylation of perhexiline 
in Wistar, Lewis and DA rats. Assay conditions as in 
Table 6.5# Lineweaver-Burk plots of computer weighted data.
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Figure 6,15. Enzyme kinetics
In vitro liver microsomal trans-hydroxylation of perhexiline 
in Wistar, Lewis and DA rats. Lineweaver-Burk plots of 
computer weighted data. Assay conditions as in Table 6.5.
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and Miller, 1949; 1953; Brodie, jrfc ail., 1955)* Mg^+ is required for 
maximal mono-oxygenase activity (Mueller and Miller, 1948; La Du, et al., 
1955).
The in vitro hydroxylation of perhexiline to cis- and trans-
monohydroxy-perhexilines by hepatic microsomes required the presence
2+of viable microsomes and addition of NADPH. Mg was required for 
maximal hydroxylase activity. Both cis- and trans-hydroxylation of 
perhexiline were inhibited by the classical inhibition of cytochrome 
P-450 dependent mono-oxygenase system, carbon monoxide (Cooper, et al., 
1965). The above data are consistent with the mediation of cytochrome 
P-450 dependent microsomal mixed function oxidase in the cis— and trans- 
hydroxylation of perhexiline.
In the Wistar rat, the apparent Vmax cis-monohydroxylation was 
about 5 times lower than that for trans-monohydroxylation of perhexiline.
The apparent for cis- and trans-hydroxylation were, however, about 
equal. In the Lewis rat the apparent V Y T°r trans-hydroxylation was 
about 7 times greater than that of cis-hydroxylation, and the apparent 
Km of trans- was about twice that of cis-hydroxylation. In the 
hydroxy la tion deficient DA rat. negative Y and K values were obtained 
(Table 6.5). The enzyme kinetic studies described in this chapter are, 
however, difficult to interpret, for a variety of reasons. For example, 
the progress curves (Figure 6.4 and 6.5) show that a plateau was reached 
when the percentage conversion of perhexiline to cis-monohydroxy perhexiline 
was only 0.002$ and to trans-metabolite was only 0.007$. The simplest 
explanation is that a steady state was approached and that the monohydroxy 
perhexilines were being metabolized further to products which were not 
determined, possibly the dihydroxy-perhexilines. Since this conversion 
would have occurred even in the 5 minute incubation used for initial
rate determination, the apparent kinetic constants are likely to be under­
estimates. A more reliable estimate of kinetic constants may have been 
obtained by a different assay procedure, using either oxygen consumption 
or NADPH utilisation. The concave downward Lineweaver-Burke plots 
of the experimental data may be due to the presence of more than one 
enzyme for the formation of both cis- and trans-monohydroxy-perhexiline. 
However, this could only be established by a much more careful kinetic 
study which took into account the factors producing the progress curves.
Microsomes from the DA rat failed to produce type 1 binding spectra 
with six drugs including debrisoquine and perhexiline despite extensive 
type I binding of these drugs to normally hydroxylating rat strains 
(Kupfer, et d,, 1982). Thus the impaired drug hydroxylation in the DA 
rat, and possibly in PM phenotypes in man, may be partly or wholly due to 
defective cytochrome P-450-substrate interaction as a result of deficient 
binding receptors or abnormal microenviroment of cytochrome P-450 (Kupfer, 
et^l., 1982).
Perhexiline enantiomers were metabolized at different rates by liver 
microsomes in all strains of rats studied, with the (—) enantiomer being 
metabolized more rapidly than either its optical antipode or the racemate. 
Trans-monohydroxy la tion was the predominant route of microsomal metabolism 
of racemic, (+) or (-) perhexiline in all rat strains.
In human microsomes the rate of cis- and trans-hydroxylation of 
perhexiline were about equal for both racemic and (+) perhexiline. Cis- 
hydroxylation was however the predominant pathway of metabolism of (—) 
perhexiline. The (—) enantiomer was metabolized more rapidly than either 
the racemate or (+) enantiomer; the rate of metabolism of (+) perhexiline 
was the slowest.
These stereoselective studies in perhexiline metabolism were carried 
out at only one substrate concentration (100 pM). Thus the mechanism of 
the enantiomeric differences in perhexiline metabolism is not known.
There is however evidence to suggest that stereoselective differences in 
hydroxylation of cyclohexyl moieties may be due either to involvement of 
multiple forms of cytochrome P-450 (May, et al,, 1975)» or to stereo- 
specific differences in binding to cytochrome P-450 (Fish, et al., 1977).
Hydroxylation of one of the cyclohexyl rings of perhexiline introduces 
a second centre of chirality in the molecule with the possible formation 
of 8 diastereomers from metabolism of racemic perhexiline (see Figure 5.1). 
Eight such diastereomers have recently been identified with GC/MS Jin vitro 
upon incubation of rat liver 10,000 g supernatant in the presence of racemic 
perhexiline; incubation in the presence of either enantiomers yielded 
4 diastereomers, two cis- and two trans- diastereomers (Burke, 1982).
The diastereomeric metabolites of perhexiline may be further metabolized 
in both rats and man to dihydroxy-perhexilines (Leeson, et al^, 1972;
Wright, et aJL., 1973)# Michaelis-Menten kinetics are thus probably not 
suitable for the in vitro microsomal cis- and trans-hydroxylation of 
perhexiline on account of the concave downward Lineweaver-Burke plots 
of experimental data, the negative kinetics of the DA rat and the complex 
stereoselective metabolism. e
The jLn vitro microsomal metabolism of perhexiline exhibited both 
substrate and substrate-product stereoselectivity in rats ^n vitro and in 
humans both _in vitro and in vivo. The pattern of metabolism in the rat 
was however different from that observed with human microsomes. The 
difference in metabolic patterns between rat and human microsomes demands 
caution in using even the hydroxylating deficient DA rat as a model for
studying the mechanism of perhexiline toxicity in humans. In view of 
the large inter-individual variation in perhexiline metabolism in humans 
the number of human microsomal samples studied were obviously inadequate 
However, the jLn vitro human microsomal study supports the stereo­
selective metabolism of perhexiline in vivo reported previously in 
Chapter 5.
For hundreds of years appropriate dosage regimes of drugs were 
determined by trial and error. With the development of modern technology 
the relationship between drug concentration and pharmacological effect is 
becoming clearer. In general, the intensity of the therapeutic and toxic 
effects of most drugs dependson their concentration at their receptor 
sites. Drug concentration at the receptor site generally correlates 
better with plasma drug concentration than with dosage. The time course 
of plasma drug concentration, and hence drug concentration at the receptor 
site, is determined by the frequency of drug administration and the rate 
of drug elimination. Thus the availability of drug pharmacokinetic data 
allows a clinician to choose the appropriate dosage regime that will 
produce and maintain a desired drug concentration in the plasmq and hence 
at the receptor site^which is compatible with maximum efficacy and maximum 
safety. Pharmacokinetic information may also be employed in making the 
necessary dosage adjustments in accordance with individual body size and 
composition, sex, age and the status' of the circulatory, renal, and hepatic 
function, and with hepatic enzyme induction which sometimes occurs following 
repeated dosage with drugs.
Considerable progress in the development of sensitive analytical 
methods for the determination of drugs in biological fluids have taken 
place in the past decade or so. Diverse techniques such as mass spectro­
metry, gas liquid chromatography, high performance liquid chromatography, 
radio-immunoassay and enzyme immunoassay have all been employed in the 
detection and quantification of low drug and/or metabolite levels in 
biological fluids and tissues following the administration of therapeutic 
doses of drugs. These advances in analytical methodology have made 
possible the pharmacokinetic studies of several drugs with immense
contribution to effective and safe pharmaco-therapy.
The efficacy of perhexiline maleate in the prophylaxis of angina 
pectoris is not in doubt, neither is its potential toxicity (Lockhart 
and Masheter, 1976; Mir-Kafetzakis, et al., 1978? Lewis, et al,.* 1979* 
Forbes, et al., 1979). It appears that inappropriate dosage schedules 
are partly to be blamed for the relatively high incidence of adverse 
reactions to the drug. For example, a higher incidence of side effects 
was associated with a daily Pexid dose of 400 mg than with 200 mg (Lockhart 
and Masheter, 1976). No adverse reactions to the drug was experienced 
by patients on 100 mg Pexid tablets twice daily (Hogan, et aJL., 1981).
The lack of rational drug therapy is partly due to the fact that no 
extensive studies of the metabolism and kinetics of the drug have been 
undertaken. Kinetic studies were not even undertaken in the animal 
safety evaluation studies, simply because no suitable analytical method 
was available.
The analysis of perhexiline and its metabolites in biological fluids
has posed considerable difficulties in the past. Earlier studies of
14perhexiline metabolism employed C-perhexiline and did not distinguish 
between unchanged perhexiline and its hydroxylated metabolites (Wright 
e_t a^., 1973). Until very recently, g.l.c. methods were the mainstay of 
drug and metabolite determination (Wright et al., 1973* Lang, et al,.* 1978 
Singlas, et al,., 1978; Cooper and Turnell, 1980). The low sensitivity 
of these procedures, however, precluded their use in single dose pharma­
cokinetic studies. Recently a very sensitive h.p.l.c. method using a 
dansyl derivative of perhexiline was developed for the determination of 
unchanged perhexiline in the plasma. The procedure was employed success­
fully in studying the pharmacokinetics of perhexiline in 5 elderly patients
with ischaemic heart disease (Horowitz, ej} a_l., 1981). The validity of 
this procedure for plasma perhexiline metabolite levels or urinary drug 
and metabolite estimations were not, however, assessed.
In the present work an ultra violet spectrophotometric h.p.l.c. 
procedure (using dinitrophenyl derivatives of drug and metabolites) 
for the simultaneous determination of perhexiline and its metabolites in 
plasma and urine was developed and validated. The procedure was of 
adequate sensitivity for single dose pharmacokinetic studies of 
perhexiline in human subjects. This analytical procedure however 
involves a rather tedious and time-consuming extraction procedure, and 
long chromatographic analysis time, making it unsuitable for routine 
therapeutic plasma drug monitoring in patients on Pexid therapy. For 
routine therapeutic drug monitoring, the Cooper and Turnell, g.l.c. 
procedure (Cooper and Turnell, 1980) is the most suitable analytical 
method; this method has been employed in monitoring the serum perhexiline 
levels in patients on Pexid therapy, with dosage adjustment to decrease 
the incidence of perhexiline induced toxicity (Cooper and Turnell, 1982).
Following oral administration of perhexiline, considerable inter~ 
individual variation in the rates of drug absorption occurs. The 
fraction of the oral dose of perhexiline absorbed could not be detected 
in the present study for practical reasons. Using a solution of 
■^C-perhexiline maleate, Wright, e_t a_l., 1973 estimated a bioavailability 
of between 52 - 95$ of the orally administered dose; these workers did 
not, however, distinguish between plasma unchanged perhexiline and 
perhexiline metabolites. In retrospect, the figure of 52 - 95$ bio­
availability appears to be an over estimation, considering the extensive 
first pass metabolism of perhexiline observed in the present study.
Pre-systemic drug metabolism was most extensive for (-)perhexiline and 
least for the (+) enantiomer. There was marked inter-individual 
variation in the "apparent systemic availability", AUC, of perhexiline 
following diug ingestion. Individual differences in intrinsic hepatic 
drug clearance may have been partly responsible (Kornhauser, ejb ajL., 1978; 
Alvan, ejfc aj.., 1977). Significantly more unchanged drug was available 
in the systemic circulation with the (+) enantiomer than with either its 
optical antipode or racemic perhexiline; the AUC of unchanged perhexiline 
after the administration of the racemate was about twice that of the (-) 
isomer.
Perhexiline is metabolized by the cytochrome P-450-dependent 
mixed-function oxidase system in the liver. The major route of metabolism 
is hydroxylation of the cyclohexyl rings. In general, cis-hydroxylation 
is the predominant pathway with trans-hydroxylation probably playing 
a major role in individuals with impaired drug oxidative capacity. Cis- 
hydroxylation may, however, exhibit saturable kinetics.
The metabolism of perhexiline exhibits complex stereoselectivity. 
Hydroxylation of either of the cyclohexyl rings introduces a second centre 
of chirality in the molecule with the possible formation of 8 diastereomers 
from racemic perhexiline (4 from each enantiomer) (Figure 5#1*)* Eight 
such diastereomers (4 cis- and 4 trans-monohydroxy-perhexilines) have 
recently been identified (Burke 1982). More than one enzyme and/or enzyme 
site may be involved in their formation. The h.p.l.c. procedure described 
in Chapter 2 could not resolve either the cis-diastereomers or the trans- 
diastereomers. The (-) enantiomer of perhexiline is metabolized at a 
faster rate both in in vivo and m  vitro than its optical antipode or the 
racemate.
Following administration of racemic perhexiline to human volunteers, 
the urinary trans-/cis-monohydroxy—perhexiline ratio was between 0.3 and 
0.9. Cis-hydroxylation was the preferred biotransformation pathway 
with (-)perhexiline. In contrast, following administration of (+) 
perhexiline, the predominant route of metabolism was trans-hydroxylation. 
Thus the predominance of cis-monohydroxy-perhexiline in the blood and 
urine in most individuals after ingestion of the racemate was largely 
due to the metabolism of the (-)enantiomer barring any unpredictable 
enantiomeric interactions.
Considerable inter-individual variation in metabolism and excretion
followed drug ingestion. Between 3 - 23$ of the administered dose of
racemic perhexiline was excreted in the urine as monohydroxy-perhexilines
in 5 days post dosage; unchanged perhexiline was either undetectable
or present in the urine in very small amounts. In a similar period
between 5 — 33$ of the administered dose of ^C, following administration 
14of C-perhexiline, was excreted in the urine, with no unchanged perhexiline 
being detected in the urine (Wright, et jal., 1973). In the present project 
the extent of faecal drug and metabolite excretion could not be assessed 
because of the lack of a suitable analytical method. In the volunteers of 
Wright and associates (1973), the excretion of radioactivity in the faeces 
was from less than half to about the same amount as was excreted in the 
urine. There was no significant difference in the plasma perhexiline 
half-lives of the three dosage forms, racemate, (+) and (-) perhexiline 
studied. Systemic drug clearance, a more sensitive indicator of drug 
elimination (Rawlins, 1980), could not, however, be determined for 
practical reasons. From the AUCs and urinary excretion data, drug 
cumulation on prolonged Pexid therapy is more likely to occur with the 
(+) enantiomer than with either the (-) enantiomer or racemate, and least 
likely with (—)Pexid.
/'Males and the elderly (Chapter 4) tended to have higher peak 
plasma perhexiline concentrations and AUCs, hut these differences were 
not statistically significant.
The molecular mechanism of perhexiline-induced toxicity is still 
not clear. There is, however, evidence to implicate impaired drug 
metabolism with consequent toxic drug cumulation (Singlas, et .al.* 1978). 
Recently Shah £t a_l., 1982, showed an association between impaired 
oxidative drug metabolic capacity and perhexiline-induced peripheral 
neuropathy. In the proposed animal model (DA rat) for the human poor 
drug metabolizer (PM) phenotype, perhexiline hydroxylation was impaired. 
Defective function of the liver mono-oxygenase system (Davies, ejfc 1981)
possibly as a result of defective cytochrome P-450-substrate interaction 
and/or abnormal microenviroment of cytochrome P-450 may be responsible for 
the genetically determined impairment in drug oxidative capacity 
(Kupfer et al., 1982).
SUGGESTIONS FOR FUTURE WORK
Attempts should be made to improve the h.p.l.c. method with a view 
to resolving the cis- and trans-diastereomers, and shortening the sample 
preparation and chromatographic analysis time. It may be worthwhile 
investigating the possible electrochemical detection of perhexiline 
and its metabolites to obviate the derivatization step.
Multiple dose pharmacokinetic studies of racemic and resolved 
perhexiline enantiomers need to be undertaken with the ultimate objective 
of choosing the appropriate dosage form and schedule for the prophylaxis 
of angina pectoris.
More extensive jln vitro studies of human liver, and possibly 
intestinal, microsomal metabolism of perhexiline and its enantiomers, 
using oxygen and/or NADPH as parameters for analysis, may help elucidate 
the mechanism of Pexid metabolism and toxicity.
Properly designed, controlled studies to assess the pharmacological 
and therapeutic differences of the perhexiline enantiomers in human 
patients should be undertaken.
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